

2024 AmeriHealth Caritas VIP Care DE DSNP

2024 Prior Authorization Criteria

CURRENT AS OF 04/01/2024

ABILIFY ASIMTUFII

Products Affected

- ABILIFY ASIMTUFII

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | The member has a documented history of receiving oral aripiprazole without any clinically significant side effects. |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | Trial of, contraindication to, or medical reason (e.g. intolerance, hypersensitivity or contraindication) for not using Abilify Maintena. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

ACITRETIN

Products Affected

- *acitretin*

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a dermatologist or an oncologist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | For prophylaxis of skin cancer in patients with previously treated skin cancers who have undergone an organ transplantation the request will be approved. For psoriasis: the patient has documented trial of, contraindication to, or medical reason for not using at least 2 of the treatment options listed: topical steroids, tazarotene, methotrexate, and cyclosporine. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

ACTEMRA

Products Affected

- ACTEMRA ACTPEN
- ACTEMRA SUBCUTANEOUS

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Specialist for submitted diagnosis. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | For pJIA: Either 1) Trial of, medical reason for not using, or contraindication to 2 of the following: Enbrel, Humira, Hadlima, or Xeljanz or 2) If utilized within the past 120 days, approve for continuation of therapy. For RA: Either 1) Trial of, medical reason for not using, or contraindication to 2 of the following: Enbrel, Humira, Hadlima, Rinvoq, or Xeljanz or 2) If utilized within the past 120 days, approve for continuation of therapy. For sJIA, Giant Cell Arteritis and Systemic Sclerosis-Associated Interstitial Lung Disease: Approve |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

ACTHAR

Products Affected

- ACTHAR

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | New starts for MS exacerbation, rheumatic disorders, collagen diseases, dermatologic diseases, serum sickness, edematous state (e.g. nephrotic syndrome without uremia), and respiratory diseases: trial of, contraindication to, or medical reason for not using 1) oral corticosteroids AND 2) Cortrophin. New starts for ophthalmic disease: trial of, contraindication to, or medical reason for not using 1) oral or ophthalmic corticosteroids AND 2) Cortrophin. Continuation of therapy or reauthorization for MS exacerbation: documentation of symptom improvement and current use of a multiple sclerosis disease modifying agent for maintenance therapy. Continuation of therapy or reauthorization for all other conditions: documented evidence of response to treatment and symptom improvement. |
| Age Restrictions | N/A |
| Prescriber Restrictions | Specialist for submitted diagnosis. |
| Coverage Duration | MS exacerbation: 1 month. Other conditions: new start for 3 months and reauth end of contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

ACTIMMUNE

Products Affected

- ACTIMMUNE

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

ADEMPAS

Products Affected

- ADEMPAS

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Concomitant use with PDE inhibitor or nitrate therapy |
| Required Medical Information | Documentation of pulmonary arterial hypertension (PAH) WHO Group I and IV classification and PAH Functional Class. Reviewer will verify available patient claim history to confirm patient is not using PDE inhibitors or nitrates. |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a pulmonologist or cardiologist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

ALPHA-1 PROTEINASE INHIBITORS

Products Affected

- ARALAST NP INTRAVENOUS SOLUTION RECONSTITUTED 1000 MG, 500 MG
- GLASSIA
- PROLASTIN-C
- ZEMAIRA

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Documentation of hereditary alpha1-antitrypsin deficiency as evident by pretreatment serum AAT levels below 11 micromol/L and progressive FEV1 or FVC decline demonstrating symptomatic lung disease. |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a pulmonologist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | If the medication request is for Glassia or Aralast NP, the patient has a documented medical reason (such as trial, intolerance or contraindication) for not using Prolastin-C or Zemaira to treat their medical condition. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

AMBRISENTAN

Products Affected

- *ambrisentan*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Documentation of pulmonary arterial hypertension (PAH) WHO Group I classification and PAH Functional Class. |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a pulmonologist or cardiologist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

APOMORPHINE

Products Affected

- *apomorphine hcl subcutaneous*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Concomitant use with serotonin 5-HT3 receptor antagonists. |
| Required Medical Information | Reviewer will verify available patient claim history to confirm patient is not using 5-HT3 receptor antagonists. |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with a neurologist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | If diagnosis is Parkinson's, the patient must have a documented trial of, contraindication to, or medical reason for not using two alternatives such as entacapone, tolcapone, rasagiline, selegiline, carbidopa/levodopa, bromocriptine, pramipexole or ropinirole. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

ARCALYST

Products Affected

- ARCALYST

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Specialist for submitted diagnosis. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | For deficiency of interleukin-1 receptor antagonist, documented trial of, contraindication to, or medical reason for not using Kineret. For continuation of therapy or reauthorization: Documentation has been provided that patient has clinically benefited from medication. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

ARISTADA

Products Affected

- ARISTADA INITIO 441 MG/1.6ML, 662 MG/2.4ML, 882
- ARISTADA INTRAMUSCULAR MG/3.2ML
PREFILLED SYRINGE 1064 MG/3.9ML,

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | The member has a documented history of receiving oral aripiprazole without any clinically significant side effects. |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | Trial of, contraindication to, or medical reason for not using Abilify Maintena. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

AUVELITY

Products Affected

- AUVELITY

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Seizure disorder |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | Trial of, contraindication to, or medical reason for not using to two generic antidepressants. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

AZTREONAM LYSINE

Products Affected

- CAYSTON

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a pulmonologist, infectious disease specialist, or an expert in the treatment of cystic fibrosis. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

BENLYSTA

Products Affected

- BENLYSTA SUBCUTANEOUS

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a rheumatologist, nephrologist, or specialist in the treatment of autoimmune disorders. |
| Coverage Duration | New starts will be authorized for 6 months. Cont of therapy or reauth until end of contract year. |
| Other Criteria | For new starts for systemic lupus erythematosus (SLE): concurrent use of two of the following or medical reason for not using glucocorticoids, azathioprine, methotrexate, mycophenolate, or hydroxychloroquine, chloroquine, and cyclophosphamide. For continuation of therapy or reauthorization for SLE: documentation of clinical response to therapy (i.e. fewer flares that required steroid treatment, lower average daily oral prednisone dose, improved daily function either as measured through a validated functional scale or through improved daily performance documented at clinic visits, etc.) For new starts for lupus nephritis (LN): concurrent use of or medical reason for not using background immunosuppressive therapy regimen. For continuation of therapy or reauthorization for LN: Documentation of improvement in renal function (i.e. reduction in UPCR). |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

BESREMI

Products Affected

- BESREMI

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a hematologist, oncologist, or specialist for submitted diagnosis. |
| Coverage Duration | The request will be authorized until the end of the contract year. |
| Other Criteria | Trial of, contraindication to, or medical reason for not using Pegasys |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

BOSENTAN

Products Affected

- *bosentan*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Documentation of pulmonary arterial hypertension (PAH) WHO Group I classification and PAH Functional Class. |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a pulmonologist or cardiologist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

BUDESONIDE ER 9 MG

Products Affected

- *budesonide er oral tablet extended release
24 hour*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized for 8 weeks. |
| Other Criteria | Patient must have a documented trial of, contraindication to, or medical reason for not using sulfasalazine, balsalazide, or an oral mesalamine product. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

CABLIVI

Products Affected

- CABLIVI

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis of acquired thrombotic thrombocytopenia purpura (aTTP) AND date of last plasma exchange |
| Age Restrictions | Patient is 18 years of age or older |
| Prescriber Restrictions | Prescribed by or in consultation with a hematologist |
| Coverage Duration | Request will be authorized until 2 months after the date of the last plasma exchange |
| Other Criteria | For new starts: Cablivi is being used in combination with plasma exchange and immunosuppressive therapy (e.g., systemic corticosteroids, cyclosporine, cyclophosphamide, mycophenolate mofetil, hydroxychloroquine) |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

CAMZYOS

Products Affected

- CAMZYOS

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with a cardiologist. |
| Coverage Duration | New starts will be authorized for 6 months. Cont of therapy or reauth until end of contract year. |
| Other Criteria | For all new starts, ALL of the following must be provided: 1) Diagnosis of symptomatic New York Heart Association (NYHA) class II or III obstructive hypertrophic cardiomyopathy (oHCM) AND 2) Patient has a left ventricular ejection fraction (LVEF) greater than or equal to 55% AND 3) Assessment of Valsalva left ventricular outflow tract (LVOT) gradient AND 4) Trial of, medical reason for not using or contraindication to BOTH of the following: Beta blockers (i.e. metoprolol, propranolol, atenolol) AND Non-dihydropyridine calcium channel blockers (i.e. verapamil, diltiazem) AND 5) Prescriber attests that patient is not using moderate to strong CYP2C19 or CYP3A4 inhibitors or inducers. For continuation of therapy or reauthorization, all of the following must be provided: 1) Documentation of clinical benefit as evidenced by an improvement from baseline in oHCM symptoms (i.e., improvement in fatigue, chest pain, shortness of breath, LVOT, peak oxygen consumption, etc.) OR improvement or no worsening of NYHA functional class AND 2) Member must also have a left ventricular ejection fraction (LVEF) greater than or equal to 50%. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

Formulary ID 24425

Last Updated: 03/2024

| PA Criteria | Criteria Details |
|--------------------------------|-------------------------|
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024
20

CARGLUMIC ACID

Products Affected

- *carglumic acid oral tablet soluble*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

CASPOFUNGIN

Products Affected

- *casposfungin acetate*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Documentation of a consultation with an infectious disease specialist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

CERDELGA

Products Affected

- CERDELGA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Patients with undetermined CYP2D6 metabolizer status. |
| Required Medical Information | Patient's CYP2D6 metabolizer status, as determined by an FDA approved test. For reauthorization, documentation has been provided that patient has obtained clinical benefit from medication (e.g. increased platelet count, improvement in anemia, PFTs, improvement in radiographic scans, improved quality of life). |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with a specialist in treatment of Gaucher's disease. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

CGRP ANTAGONISTS

Products Affected

- AIMOVIG
- EMGALITY
- EMGALITY (300 MG DOSE)
- NURTEC
- UBRELVY
- ZAVZPRET

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | New starts will be authorized for 6 months. Cont of therapy or reauth until end of contract year. |
| Other Criteria | For acute migraine new starts - for Ubrelvy and Nurtec requests, must have trial of, contraindication to or medical reason for not using a triptan. For migraine prophylaxis new starts - 1) at least 4 migraine days per month or one or more severe migraine attacks lasting for greater than 12 hours despite use of abortive therapy (e.g. triptans or NSAIDs) and 2) trial of, contraindication to, or medical reason for not using at least two of the following agents: a beta adrenergic blocker, an anti-epileptic agent, a tricyclic antidepressant, or a serotonin-norepinephrine reuptake inhibitor. For Emgality requests for episodic cluster headache new starts - must have trial of, contraindication to, or a medical reason for not using verapamil for at least 4 weeks at minimum effective doses. For continuation of therapy or reauthorization - For acute migraine (Nurtec, Ubrelvy), must show documentation of improvement in migraine symptoms (pain, photophobia, phonophobia). For migraine prevention (Nurtec, Emgality, Aimovig), must show a benefit of 1 headache day per month reduction since initiation of therapy. For episodic cluster headache treatment, must show documentation of reduction in frequency of headaches |
| Indications | All Medically-accepted Indications. |

Formulary ID 24425

Last Updated: 03/2024

| PA Criteria | Criteria Details |
|----------------------------|-------------------------|
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

CHOLBAM

Products Affected

- CHOLBAM

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | For new starts: Patient has documented diagnosis of either: 1) bile acid synthesis disorder due to a single enzyme defect or 2) peroxisomal disorders. For continuation of therapy or reauthorization: prescriber attests: 1) the patient has clinical improvement with therapy (i.e. liver function tests) AND 2) there is no evidence of biliary obstruction or cholestasis |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a hepatologist, gastroenterologist, or metabolic specialist |
| Coverage Duration | New starts will be authorized for 3 months. Cont of therapy or reauth until end of contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

CIBINQO

Products Affected

- CIBINQO

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Specialist for submitted diagnosis. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | For atopic dermatitis: Trial of, contraindication to, or medical reason for not using Rinvoq |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

CIMZIA

Products Affected

- CIMZIA STARTER KIT
SUBCUTANEOUS PREFILLED
SYRINGE KIT
- CIMZIA SUBCUTANEOUS KIT 2 X 200
MG
- CIMZIA SUBCUTANEOUS
PREFILLED SYRINGE KIT

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Specialist for submitted diagnosis. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | For ankylosing spondylitis: Either 1) Trial of, medical reason for not using, or contraindication to 2 of the following therapies: Enbrel, Humira, Hadlima, Rinvoq or Xeljanz or 2) If utilized within the past 120 days, approve for continuation of therapy. For Crohns Disease: Either 1) Trial of, medical reason for not using, or contraindication to 2 of the following therapies: Humira, Hadlima, Skyrizi or Stelara or 2) If utilized within the past 120 days, approve for continuation of therapy. For non-radiographic axial spondyloarthritis: approve. For psoriasis: Either 1) Trial of, medical reason for not using, or contraindication to 2 of the following therapies: Skyrizi, Tremfya, Stelara, Enbrel, Hadlima, or Humira 2) If utilized within the past 120 days, approve for continuation of therapy. For PsA: Either 1) Trial of, medical reason for not using, or contraindication to 2 of the following therapies: Stelara, Skyrizi, Tremfya, Xeljanz, Rinvoq, Enbrel, Hadlima, or Humira, or 2) If utilized within the past 120 days, approve for continuation of therapy. For RA: Either 1) Trial of, medical reason for not using, or contraindication to 2 of the following: Enbrel, Humira, Hadlima, Rinvoq or Xeljanz or 2) If utilized within the past 120 days, approve for continuation of therapy |

Formulary ID 24425

Last Updated: 03/2024

| PA Criteria | Criteria Details |
|----------------------------|-------------------------------------|
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

CORLANOR

Products Affected

- CORLANOR

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Blood pressure less than 90/50 mmHg |
| Required Medical Information | New starts for chronic heart failure must have all of the following: 1) LVEF of 35% or less 2) Sinus rhythm and have resting heart rate greater than or equal to 70 bpm 3) Blood pressure greater than or equal to 90/50 mmHg |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a cardiologist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | Trial of, contraindication to, or medical reason for not receiving a beta blocker. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

CORTROPHIN

Products Affected

- CORTROPHIN

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | New starts for MS exacerbation, rheumatic disorders, collagen diseases, dermatologic diseases, serum sickness, edematous state (e.g. nephrotic syndrome without uremia), and respiratory diseases: trial of, contraindication to, or medical reason for not using oral corticosteroids. New starts for ophthalmic disease: trial of, contraindication to, or medical reason for not using oral or ophthalmic corticosteroids. Continuation of therapy or reauthorization for MS exacerbation: documentation of symptom improvement and current use of a multiple sclerosis disease modifying agent for maintenance therapy. Continuation of therapy or reauthorization for all other conditions: documented evidence of response to treatment and symptom improvement. |
| Age Restrictions | N/A |
| Prescriber Restrictions | Specialist for submitted diagnosis. |
| Coverage Duration | MS exacerbation: 1 month. Other conditions: new start for 3 months and reauth end of contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

COSENTYX

Products Affected

- COSENTYX
- COSENTYX (300 MG DOSE)
- COSENTYX SENSOREADY (300 MG)
- COSENTYX SENSOREADY PEN
- COSENTYX UNOREADY

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Specialist for submitted diagnosis. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | For ankylosing spondylitis: Either 1) Trial of, medical reason for not using, or contraindication to 2 of the following therapies: Enbrel, Humira, Hadlima, Rinvoq or Xeljanz, or 2) If utilized within the past 120 days, approve for continuation of therapy. For non-radiographic axial spondyloarthritis: approve. For psoriasis: Either 1) Trial of, medical reason for not using, or contraindication to 2 of the following therapies: Stelara, Skyrizi, Tremfya, Enbrel, Hadlima, or Humira, or 2) If utilized within the past 120 days, approve for continuation of therapy. For PsA: Either 1) Trial of, medical reason for not using, or contraindication (e.g., safety concerns, not indicated for patients age) to 2 of the following therapies: Stelara, Skyrizi, Tremfya, Xeljanz, Rinvoq, Enbrel, Hadlima, or Humira, or 2) If utilized within the past 120 days, approve for continuation of therapy. For enthesitis-related arthritis: approve. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

CYSTAGON

Products Affected

- CYSTAGON

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

CYSTARAN

Products Affected

- CYSTARAN

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Documentation of diagnosis for cystinosis with corneal cystine crystal accumulation. |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with an ophthalmologist or metabolic disease specialist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

DALFAMPRIDINE ER

Products Affected

- *dalfampridine er*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | History of seizure or moderate/severe renal impairment (CrCl less than or equal to 50 mL/min). |
| Required Medical Information | For new starts: 1) Attestation that creatinine clearance (CrCl) greater than 50 mL/min was confirmed prior to initiation of therapy, AND 2) Documentation has been provided that member is ambulatory (able to walk at least 25 feet) and has a documented walking impairment, AND 3) For appropriate indications, member is currently being treated with a disease modifying agent (e.g. immunomodulator, interferon, etc.) or has a medical reason why member is unable to use a disease modifying agent for their condition. For continuation of therapy or re-authorization requests: 1) Member must experience improvement in walking from baseline due to use of dalfampridine ER. |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a neurologist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

DEFERASIROX

Products Affected

- *deferasirox*
- *deferasirox granules*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Creatinine clearance less than 40 mL/min or platelet counts less than 50,000/mm ³ . |
| Required Medical Information | For all indications: platelet count greater than or equal to 50,000/mm ³ (within 30 days) and creatinine clearance greater than or equal to 40 mL/min. For chronic iron overload due to transfusions: serum ferritin concentration greater than 1000 mcg/L (lab result with 30 days). For chronic iron overload in non-transfusion-dependent thalassemia syndromes: serum ferritin concentration greater than 300 mcg/L (lab result with 30 days). |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | For deferasirox granules oral packets, the member must have medical reason for not using deferasirox tablets or oral soluble tablets. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

DEFERIPRONE

Products Affected

- *deferiprone*

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | For new starts: 1) serum ferritin level above 1,000 mcg/L and absolute neutrophil count (ANC) greater than $1.5 \times 10^9/L$ within 30 days of request, and 2) Trial of, contraindication to, or medical reason for not using deferasirox tablets. For continuation of therapy or reauthorization, decrease in serum ferritin from baseline. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

DIACOMIT

Products Affected

- DIACOMIT

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a neurologist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | For members 2 years and older: Trial of, contraindication to, or medical reason for not using one generic anticonvulsant for appropriate indications. For members under 2 years old: Approve. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

DICHLORPHENAMIDE

Products Affected

- *dichlorphenamide*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with a geneticist, neurologist, or endocrinologist. |
| Coverage Duration | New starts will be authorized for 2 months. Cont of therapy or reauth until end of contract year. |
| Other Criteria | Continuation of therapy or reauthorization: documentation of clinical improvement with therapy. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

DIFICID

Products Affected

- DIFICID

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized for 10 days. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

DOPTELET

Products Affected

- DOPTELET

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | For new starts for chronic liver disease and chronic immune thrombocytopenia (chronic ITP): documented baseline platelet count of less than 50,000/mcL. |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with hematologist, hepatologist or surgeon. |
| Coverage Duration | For thrombocytopenia with CLD getting procedure: 5 days. For chronic ITP: remainder of contract year |
| Other Criteria | For chronic ITP: trial of, contraindication to, or medical reason for not using a corticosteroid. For thrombocytopenia with chronic liver disease (CLD): approve. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

DOXEPIN CREAM

Products Affected

- *doxepin hcl external*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized for 1 month. |
| Other Criteria | Trial of, contraindication to, or medical reason for not using a topical corticosteroid or topical calcineurin inhibitor. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

DUPIXENT

Products Affected

- DUPIXENT

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Specialist for submitted diagnosis. |
| Coverage Duration | New starts will be authorized for 6 months. Cont of therapy or reauth until end of contract year. |
| Other Criteria | New starts for atopic dermatitis in patients 2 years old or older: trial of, contraindication to, or medical reason for not using: 1) topical tacrolimus or pimecrolimus and 2) Eucrisa. New starts for atopic dermatitis in patients less than 2 years old: trial of, contraindication to, or medical reason for not using Eucrisa. New starts for asthma with eosinophilic phenotype: 1) blood eosinophil count greater than or equal to 150 cells per microliter, and 2) symptoms persist with at least 1 exacerbation in the last 12 months requiring additional treatment (e.g. oral systemic steroids) while on a high dose inhaled corticosteroid with an additional controller medication (ie. long-acting B2 agonist). New starts for oral corticosteroid dependent asthma: symptoms persist with at least 1 exacerbation in the last 12 months requiring additional treatment, (e.g. oral systemic steroids) while on a high dose inhaled corticosteroid with an additional controller medication (ie. long-acting B2 agonist). New starts for chronic rhinosinusitis with nasal polyps: trial of, contraindication to, or medical reason for not using nasal corticosteroids OR member has had prior surgery for nasal polyps. New starts for prurigo nodularis: attestation is provided confirming diagnosis. Continuation of therapy or reauthorization for all indications: clinical benefit from use of the drug. |
| Indications | All Medically-accepted Indications. |

Formulary ID 24425

Last Updated: 03/2024

| PA Criteria | Criteria Details |
|----------------------------|-------------------------|
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

EGRIFTA

Products Affected

- EGRIFTA SV

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Documentation of active antiretroviral therapy for at least 8 weeks. |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

EMSAM

Products Affected

- EMSAM

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | concomitant use with SSRIs, SNRIs, clomipramine and imipramine, meperidine, tramadol, methadone, pentazocine, and propoxyphene, and the antitussive agent dextromethorphan or carbamazepine |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | For new starts: Trial of, contraindication to, or medical reason for not using two generic antidepressants. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

ENBREL

Products Affected

- ENBREL MINI
- ENBREL SUBCUTANEOUS SOLUTION 25 MG/0.5ML
- ENBREL SUBCUTANEOUS SOLUTION PREFILLED SYRINGE
- ENBREL SUBCUTANEOUS SOLUTION RECONSTITUTED
- ENBREL SURECLICK SUBCUTANEOUS SOLUTION AUTO-INJECTOR

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Specialist for submitted diagnosis. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | For RA: Trial of, medical reason for not using, or contraindication to 1 disease modifying antirheumatic drug (DMARD) (methotrexate, leflunomide, or sulfasalazine). For pJIA: Trial of, medical reason for not using, or contraindication to 1 of the following DMARDs: methotrexate or leflunomide. For PsA or psoriasis: approve. For ankylosing spondylitis: Trial of, medical reason for not using, or contraindication to naproxen. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

ENDARI

Products Affected

- ENDARI

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Documentation that two or more painful sickle cell crises have occurred in the past 12 months. |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a hematologist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | Trial of, contraindication to, or medical reason for not using hydroxyurea for at least three months. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

ENTYVIO

Products Affected

- ENTYVIO SUBCUTANEOUS

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Specialist for submitted diagnosis. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | For ulcerative colitis: Either 1) Trial of, medical reason for not using, or contraindication to 2 of the following therapies: Stelara, Hadlima or Humira. 2) If utilized within the past 120 days, approve for continuation of therapy. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

EPIDIOLEX

Products Affected

- EPIDIOLEX

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a neurologist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | Trial of, contraindication to, or medical reason for not using one generic anticonvulsant for appropriate indications. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

EPRONTIA

Products Affected

- EPRONTIA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | The request will be authorized until the end of the contract year. |
| Other Criteria | Documented trial of, contraindication to, or medical reason for not using topiramate. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

ERYTHROPOETIN STIMULATING AGENTS

Products Affected

- ARANESP (ALBUMIN FREE) INJECTION SOLUTION 100 MCG/ML, 200 MCG/ML, 25 MCG/ML, 40 MCG/ML, 60 MCG/ML
- ARANESP (ALBUMIN FREE) INJECTION SOLUTION PREFILLED SYRINGE
- EPOGEN INJECTION SOLUTION 10000 UNIT/ML, 2000 UNIT/ML, 20000 UNIT/ML, 3000 UNIT/ML, 4000 UNIT/ML, 40000 UNIT/ML
- PROCIT
- RETACRIT INJECTION SOLUTION 10000 UNIT/ML, 10000 UNIT/ML(1ML), 2000 UNIT/ML, 20000 UNIT/ML, 3000 UNIT/ML, 4000 UNIT/ML, 40000 UNIT/ML

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | For new starts for all indications: Hgb within compendia range for treatment of the requested medical condition. For continuation of therapy or re-authorization: Hgb must not exceed 10 g/dL (anemia related to cancer), 11 g/dL (anemia of CKD), 12 g/dL (zidovudine-related anemia in members with HIV and ribavirin-induced anemia), 13 g/dL (elective, noncardiac, nonvascular surgery needing red blood cell allogeneic transfusion reduction). |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized for 6 months. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

EUCRISA

Products Affected

- EUCRISA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a dermatologist, immunologist or an allergist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | Trial of, contraindication to, or medical reason for not using topical tacrolimus or pimecrolimus. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

EVRYSDI

Products Affected

- EVRYSDI

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | For new starts, all of the following must be included: 1) Documentation of genetic testing confirming diagnosis AND 2) Documentation of baseline motor function or motor milestone achievement [e.g. CHOP Infant Test of Neuromuscular Disorders (CHOP-INTEND) or Hammersmith Infant Neurological Examination (HINE) for Type 1 or Hammersmith Functional Motor Scale Expanded Scores (HFMSE) for Type II and Type III, or 6 minute walk test in subjects able to walk]. For continuation of therapy or reauthorization, documentation of clinical response has been submitted (e.g. improvement in motor function/motor milestone achievement scores using CHOP-INTEND or HFMSE, 6 minute walk test or HINE improvement in more categories of motor milestones than worsening). |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a neurologist. |
| Coverage Duration | New starts will be authorized for 6 months. Cont of therapy or reauth until end of contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

FABHALTA

Products Affected

- FABHALTA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a hematologist |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

FASENRA

Products Affected

- FASENRA
- FASENRA PEN

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Specialist for submitted diagnosis. |
| Coverage Duration | New starts will be authorized for 6 months. Cont of therapy or reauth until end of contract year. |
| Other Criteria | New starts for severe asthma with an eosinophilic phenotype: 1)Baseline blood eosinophil count greater than or equal to 150 cells per microliter AND 2) symptoms persist with at least 1 exacerbation in the last 12 months requiring additional treatment (e.g. oral systemic steroids) while on a high dose inhaled corticosteroid with an additional controller medication (ie. long-acting B2 agonist). Continuation of therapy or re-authorization for severe asthma with an eosinophilic phenotype: clinical benefit from use of the drug. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

FENTANYL CITRATE TRANSMUCOSAL PRODUCTS

Products Affected

- *fentanyl citrate buccal lozenge on a handle*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Documentation must be provided for the all of the following: 1) fentanyl citrate oral transmucosal is being prescribed to treat cancer-related breakthrough pain AND 2) Patient has been taking opioids at a dose equal to 60 MME per day for at least one week. |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

FILSPARI

Products Affected

- FILSPARI

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Coadministration with renin-angiotensin-aldosterone system (RAAS) inhibitors, endothelin receptor antagonists, or aliskiren |
| Required Medical Information | For new starts: Attestation that member has diagnosis of primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression. Member has an estimated glomerular filtration rate (eGFR) greater than or equal to 30 mL/min/1.73 m(2) and proteinuria. For continuation of therapy or reauthorization: Documentation of positive clinical response (ie. decrease in urine protein-to-creatinine ratio (UPCR)). |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with a nephrologist. |
| Coverage Duration | New starts will be authorized for 9 months. Cont of therapy or reauth until end of contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

FINTEPLA

Products Affected

- FINTEPLA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a neurologist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | Trial of, contraindication to, or medical reason for not using one generic anticonvulsant for appropriate indications. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

FIRDAPSE

Products Affected

- FIRDAPSE

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | History of seizures. |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a neurologist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

FLUCYTOSINE

Products Affected

- *flucytosine oral*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Complete dihydropyrimidine dehydrogenase (DPD) enzyme deficiency |
| Required Medical Information | Attestation member is taking in combination with amphotericin B. |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

FLUOROURACIL

Products Affected

- *fluorouracil external cream 0.5 %*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with a dermatologist or oncologist. |
| Coverage Duration | Request will be authorized for 12 weeks. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

GALAFOLD

Products Affected

- GALAFOLD

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

GATTEX

Products Affected

- GATTEX

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | For new starts: attestation of 1) Colonoscopy of full colon with removal of polyps within six months prior to starting treatment for adults or 2) Fecal occult blood testing within six months prior to starting treatment for pediatric patients. For continuation of therapy or reauthorization: Documentation is provided that the member has obtained a clinical benefit (e.g. reduction in parenteral fluid volume, reduction in number of days receiving parenteral nutrition). |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with a gastroenterologist. |
| Coverage Duration | New starts will be authorized for 6 months. Cont of therapy or reauth until end of contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

GNRH AGONISTS

Products Affected

- CAMCEVI
- ELIGARD
- FIRMAGON (240 MG DOSE)
- FIRMAGON SUBCUTANEOUS SOLUTION RECONSTITUTED 80 MG
- *leuprolide acetate (3 month)*
- LUPRON DEPOT (1-MONTH)
- LUPRON DEPOT (3-MONTH)
- LUPRON DEPOT (4-MONTH)
- LUPRON DEPOT (6-MONTH)
- TRELSTAR MIXJECT

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | If the medication request is for the treatment of prostate cancer and if the request is for any other GnRH agonist other than Eligard or leuprolide, the patient must have a documented trial of, contraindication to, or medical reason for not using Eligard or leuprolide to treat their prostate cancer. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

GOCOVRI

Products Affected

- GOCOVRI

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with a neurologist. |
| Coverage Duration | New starts will be authorized for 3 months. Cont of therapy or reauth until end of contract year. |
| Other Criteria | New starts: trial of, contraindication to, or medical reason for not using generic amantadine. Continuation of therapy or reauthorization: Member demonstrates clinical benefit (i.e. improvement in levodopa-induced dyskinesia or decreased off episodes). |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

GROWTH HORMONES

Products Affected

- GENOTROPIN MINIQUICK SUBCUTANEOUS PREFILLED SYRINGE
- GENOTROPIN SUBCUTANEOUS CARTRIDGE
- HUMATROPE INJECTION CARTRIDGE
- NGENLA
- NORDITROPIN FLEXPRO SUBCUTANEOUS SOLUTION PEN-INJECTOR
- NUTROPIN AQ NUSPIN 10 SUBCUTANEOUS SOLUTION PEN-INJECTOR
- NUTROPIN AQ NUSPIN 20 SUBCUTANEOUS SOLUTION PEN-INJECTOR
- NUTROPIN AQ NUSPIN 5 SUBCUTANEOUS SOLUTION PEN-INJECTOR
- OMNITROPE SUBCUTANEOUS SOLUTION CARTRIDGE
- OMNITROPE SUBCUTANEOUS SOLUTION RECONSTITUTED
- SKYTROFA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | For new starts for growth hormone deficiency: Documentation showing bone age testing, height, weight, and Growth Hormone Stimulation Test results OR Insulin Growth Factor 1 level. For continuation of therapy or reauthorization for growth hormone deficiency: documentation (medical records) showing positive response to treatment. |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be an endocrinologist or nephrologist. |
| Coverage Duration | New starts will be authorized for 6 months. Cont of therapy or reauth until end of contract year. |
| Other Criteria | For new starts for growth hormone deficiency: 1) If the request is not for Genotropin, trial of, contraindication to, or medical reason for not using Genotropin. For requests for all other medically accepted indications other than growth hormone deficiency, the request will be approved for products other than Skytrofa. |
| Indications | All Medically-accepted Indications. |

Formulary ID 24425

Last Updated: 03/2024

| PA Criteria | Criteria Details |
|----------------------------|-------------------------|
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

HADLIMA

Products Affected

- HADLIMA
- HADLIMA PUSHTOUCH

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Specialist for submitted diagnosis. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | For ankylosing spondylitis: Trial of, medical reason for not using, or contraindication to naproxen. For Crohns Disease: Trial of, medical reason for not using (i.e. severe Crohns disease), or contraindication to 1 of the following: mercaptopurine, azathioprine, sulfasalazine, methotrexate or corticosteroid (e.g., prednisone, methylprednisolone). For pJIA: Trial of, medical reason for not using, or contraindication to 1 of the following DMARDs: methotrexate or leflunomide. For RA: Trial of, medical reason for not using, or contraindication to 1 disease modifying antirheumatic drug (DMARD) (methotrexate, leflunomide, or sulfasalazine). For UC: Trial of, medical reason for not using, or contraindication to 1 of the following conventional therapies: mercaptopurine, an aminosalicylate (i.e. mesalamine, sulfasalazine, azathioprine), or a corticosteroid (i.e. prednisone, methylprednisolone). For PsA, psoriasis, Hidradenitis Suppurativa, or Uveitis: approve. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

HEREDITARY ANGIOEDEMA AGENTS

Products Affected

- CINRYZE
- HAEGARDA
- ORLADEYO

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be an allergist, immunologist, rheumatologist or hematologist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | For continuation of therapy or reauthorization: Documentation has been provided that patient has clinically benefited from medication. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

HETLIOZ

Products Affected

- HETLIOZ LQ
- *tasimelteon*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | For new starts of non-24 hour sleep-wake cycle: 1) Member is totally blind with no perception of light, 2) diagnosis of non-24 confirmed by a physiologic circadian phase marker (ex: dim light melatonin onset, assessment of core body temp or measurement of urinary melatonin levels) OR actigraphy with evaluation of sleep logs. For continuation of therapy or reauthorization: documentation of clinical benefit from use of the drug. For night-time sleep disturbances in Smith-Magenis Syndrome (SMS): approve |
| Age Restrictions | N/A |
| Prescriber Restrictions | Provider is a sleep specialist or neurologist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

HIGH DOSE OPIOID

Products Affected

- *fentanyl transdermal patch 72 hour 100 mcg/hr*
- *methadone hcl oral tablet 10 mg*
- *morphine sulfate er oral tablet extended release 100 mg, 200 mg*
- *oxycodone hcl er oral tablet er 12 hour abuse-deterrent 80 mg*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | Members being treated for active cancer diagnoses, sickle cell diagnoses, those in hospice care, or receiving palliative care will be approved. For new starts, ALL of the following are required: (1) Taking opioids at a dose equal to 60 MME per day for at least one week, (2) Current regimen is the lowest possible effective dose of opioid therapy, (3) If member is on concurrent benzodiazepines and/or muscle relaxant therapy, the prescriber attests that concurrent therapy is medically necessary (4) Member is not being treated for substance abuse with buprenorphine-containing products. For continuing therapy, ALL of the following are required: (1) Member's pain has been assessed within the last 6 months, (2) Member has demonstrated clinical improvement in pain and function on current medication regimen, (3) If member is on concurrent benzodiazepines and/or muscle relaxant therapy, the prescriber attests that concurrent therapy is medically necessary, (4) Member is not being treated for substance abuse with buprenorphine-containing products. |
| Indications | All Medically-accepted Indications. |

Formulary ID 24425

Last Updated: 03/2024

72

| PA Criteria | Criteria Details |
|----------------------------|-------------------------|
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

HIGH RISK MEDICATION

Products Affected

- *clemastine fumarate oral tablet 2.68 mg*
- *cyproheptadine hcl oral*
- *dipyridamole oral*
- *disopyramide phosphate oral*
- *glyburide micronized oral tablet 1.5 mg, 3 mg, 6 mg*
- *glyburide oral tablet 1.25 mg, 2.5 mg, 5 mg*
- *glyburide-metformin oral tablet 1.25-250 mg, 2.5-500 mg*
- *glyburide-metformin oral tablet 5-500 mg*
- *guanfacine hcl er*
- *guanfacine hcl oral*
- *hydroxyzine hcl oral syrup*
- *hydroxyzine hcl oral tablet 25 mg, 50 mg*
- *hydroxyzine pamoate oral*
- *indomethacin er*
- *indomethacin oral capsule 25 mg, 50 mg*
- *ketorolac tromethamine oral*
- *megestrol acetate oral suspension*
- *nifedipine oral*
- **NORPACE CR**
- *pentazocine-naloxone hcl*
- *promethazine hcl oral*
- *promethazine hcl rectal suppository 12.5 mg, 25 mg*
- *promethazine vc*
- *promethazine-phenylephrine*
- *promethegan rectal suppository 50 mg*
- *trihexyphenidyl hcl*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | For patients 65 years old and older the prescriber has documented: 1) the benefits of treatment with the drug outweigh the potential risks identified for people 65 years old and older, and 2) the risks and side effects have been discussed and will be monitored. |
| Age Restrictions | Prior authorization only applies to members 65 years old or older. |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

Formulary ID 24425

Last Updated: 03/2024

| PA Criteria | Criteria Details |
|--------------------------------|-------------------------|
| Part B Prerequisite | No |

HIGH RISK MEDICATION - PROTECTED CLASS DRUGS

Products Affected

- *amitriptyline hcl oral*
- *amoxapine*
- *clomipramine hcl oral*
- *doxepin hcl oral capsule*
- *doxepin hcl oral concentrate*
- *imipramine hcl oral*
- *imipramine pamoate*
- *megestrol acetate oral tablet*
- MENEST
- *perphenazine-amitriptyline*
- *phenobarbital oral elixir*
- *phenobarbital oral tablet*
- *protriptyline hcl*
- *trimipramine maleate oral*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | For patients 65 years old and older the prescriber has documented: 1) the benefits of treatment with the drug outweigh the potential risks identified for people 65 years old and older, and 2) the risks and side effects have been discussed and will be monitored. |
| Age Restrictions | Prior authorization only applies to members 65 years old or older. |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

HIGH RISK MEDICATION, BUTALBITAL

Products Affected

- *ascomp-codeine*
- *bac*
- *butalbital-acetaminophen oral tablet 50-325 mg*
- *butalbital-apap-caff-cod oral capsule 50-325-40-30 mg*
- *butalbital-apap-caffeine oral capsule 50-325-40 mg*
- *butalbital-apap-caffeine oral tablet 50-325-40 mg*
- *butalbital-asa-caff-codeine*
- *butalbital-aspirin-caffeine oral capsule*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | For patients 65 years old and older the prescriber has documented: 1) the benefits of treatment with the drug outweigh the potential risks identified for people 65 years old and older, and 2) the risks and side effects have been discussed and will be monitored. |
| Age Restrictions | Prior authorization only applies to members 65 years old or older. |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | Trial of, contraindication to, or medical reason for not using an oral NSAID. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

HIGH RISK MEDICATION, SHORT TERM MUSCLE RELAXANT

Products Affected

- *carisoprodol oral*
- *chlorzoxazone oral tablet 500 mg*
- *cyclobenzaprine hcl oral tablet 10 mg, 5 mg*
- *metaxalone oral tablet 800 mg*
- *methocarbamol oral tablet 500 mg, 750 mg*
- *orphenadrine citrate er*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | For patients 65 years old and older the prescriber has documented: 1) the benefits of treatment with the drug outweigh the potential risks identified for people 65 years old and older, and 2) the risks and side effects have been discussed and will be monitored. |
| Age Restrictions | Prior authorization only applies to members 65 years old or older. |
| Prescriber Restrictions | N/A |
| Coverage Duration | New starts will be authorized for 30 days. Continuation of therapy or reauth will be for 90 days. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

HIGH RISK MEDICATION, SLEEP AGENTS

Products Affected

- *eszopiclone*
- *temazepam*
- *zaleplon*
- *zolpidem tartrate er*
- *zolpidem tartrate oral tablet 10 mg*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | For patients 65 years old and older the prescriber has documented: 1) the benefits of treatment with the drug outweigh the potential risks identified for people 65 years old and older, and 2) the risks and side effects have been discussed and will be monitored. For zolpidem immediate release 10mg and zolpidem ER: trial of or medical reason for not using zolpidem immediate release 5mg. |
| Age Restrictions | Prior authorization only applies to members 65 years old or older. |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

HUMIRA

Products Affected

- HUMIRA (2 PEN)
- HUMIRA (2 SYRINGE)
SUBCUTANEOUS PREFILLED SYRINGE KIT 10 MG/0.1ML, 20 MG/0.2ML, 40 MG/0.4ML, 40 MG/0.8ML
- HUMIRA-CD/UC/HS STARTER
SUBCUTANEOUS PEN-INJECTOR KIT 80 MG/0.8ML
- HUMIRA-PED<40KG CROHNS STARTER
- HUMIRA-PED>=40KG CROHNS START
- HUMIRA-PED>=40KG UC STARTER
- HUMIRA-PS/UV/ADOL HS STARTER
- HUMIRA-PSORIASIS/UVEIT STARTER

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Specialist for submitted diagnosis. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | For ankylosing spondylitis: Trial of, medical reason for not using, or contraindication to naproxen. For Crohns Disease: Trial of, medical reason for not using (i.e. severe Crohns disease), or contraindication to 1 of the following: mercaptopurine, azathioprine, sulfasalazine, methotrexate or corticosteroid (e.g., prednisone, methylprednisolone). For pJIA: Trial of, medical reason for not using, or contraindication to 1 of the following DMARDs: methotrexate or leflunomide. For RA: Trial of, medical reason for not using, or contraindication to 1 disease modifying antirheumatic drug (DMARD) (methotrexate, leflunomide, or sulfasalazine). For UC: Trial of, medical reason for not using, or contraindication to 1 of the following conventional therapies: mercaptopurine, an aminosalicylate (i.e. mesalamine, sulfasalazine, azathioprine), or a corticosteroid (i.e. prednisone, methylprednisolone). For PsA, psoriasis, Hidradenitis Suppurativa, or Uveitis: approve. |

Formulary ID 24425

Last Updated: 03/2024

| PA Criteria | Criteria Details |
|----------------------------|-------------------------------------|
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

HYFTOR

Products Affected

- HYFTOR

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | For new starts: documentation of diagnosis of tuberous sclerosis with facial angiofibroma. For continuation of therapy or reauthorization: documentation that the member has experienced a clinical benefit from treatment (e.g. improvement in size and color of angiofibroma). |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with a neurologist or provider who specializes in the treatment of genetic or dermatologic disorders. |
| Coverage Duration | New starts: 3 months. Cont. of therapy or reauthorization: until end of contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

ICATIBANT

Products Affected

- *icatibant acetate subcutaneous solution prefilled syringe*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be an immunologist, allergist, rheumatologist, or hematologist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

ICOSAPENT

Products Affected

- *icosapent ethyl*

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | For a diagnosis of hypertriglyceridemia: Documented trial of, contraindication to, or medical reason for not using statins at maximum tolerated dose OR documented statin intolerance AND omega-3-acid ethyl esters capsule. For a diagnosis of cardiovascular risk reduction, ALL the following are required: 1) Documentation of hypertriglyceridemia greater than or equal to 150 mg/dL: 2) Documented trial of, contraindication to, or medical reason for not using statins at maximum tolerated dose for 3 months OR documented statin intolerance AND 3) Documentation of one of the following: Established atherosclerotic cardiovascular disease (e.g., coronary artery disease, cerebrovascular accident, carotid disease, peripheral artery disease) OR age greater than or equal to 50 years old with established diabetes and at least one additional risk factor for cardiovascular disease (e.g., hypertension, renal dysfunction, retinopathy, albuminuria, males age greater than or equal to 55 years old or females age greater than or equal to 65 years old). |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

ILARIS

Products Affected

- ILARIS SUBCUTANEOUS SOLUTION

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Documentation was submitted indicating that the member was evaluated for active or latent TB infection (i.e. tuberculin skin test) |
| Age Restrictions | N/A |
| Prescriber Restrictions | Specialist for submitted diagnosis. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | For sJIA: approve. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

ILUMYA

Products Affected

- ILUMYA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Specialist for submitted diagnosis. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | For psoriasis: Either 1) Trial of, medical reason for not using, or contraindication to 2 of the following therapies: Stelara, Skyrizi, Tremfya, Enbrel, Hadlima, or Humira, or 2) If utilized within the past 120 days, approve for continuation of therapy. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

IMBRUVICA

Products Affected

- IMBRUVICA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be an oncologist or specialist for submitted diagnosis. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | For new starts for treatment of graft-versus-host disease (GVHD): Trial of, contraindication to, or medical reason for not using a systemic corticosteroid. For continuation of therapy of for treatment of GVHD: documentation of clinical benefit from use of the drug (i.e. symptom improvement, reduction in corticosteroid dose). For all other indications, approve. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

INCRELEX

Products Affected

- INCRELEX

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with an endocrinologist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

INTRON-A

Products Affected

- INTRON A INJECTION SOLUTION
RECONSTITUTED

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Specialist for submitted diagnosis. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

JAKAFI

Products Affected

- JAKAFI

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be an oncologist or specialist for submitted diagnosis. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | For new starts for treatment of graft-versus-host disease (GVHD): Trial of, contraindication to, or medical reason for not using a systemic corticosteroid. For continuation of therapy of for treatment of GVHD: documentation of clinical benefit from use of the drug (i.e. symptom improvement, reduction in corticosteroid dose). For all other indications, approve. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

KALYDECO

Products Affected

- KALYDECO

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Combination use with Orkambi, Symdeko, or Trikafta. |
| Required Medical Information | Documentation of CFTR gene that is responsive to ivacaftor treatment. |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a pulmonologist or an expert in the treatment of cystic fibrosis. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

KERENDIA

Products Affected

- KERENDIA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | New starts will be authorized for 3 months. Cont of therapy or reauth until end of contract year. |
| Other Criteria | For new starts: 1) Documentation of diagnosis of chronic kidney disease due to type 2 diabetes mellitus AND 2) Documentation of serum potassium levels less than or equal to 5 mEq/L AND 3) eGFR greater than or equal to 25ml/min/1.73 m ² AND 4) Documentation that member is taking Kerendia in combination with an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) at maximum tolerated doses or documentation has been provided that the member is unable to tolerate ACEi or ARB AND 4) Documented trial of, contraindication to, or medical reason for not using a sodium-glucose cotransporter-2 (SGLT2) inhibitor. For continuation of therapy or reauthorization: 1) Documentation of serum potassium levels less than or equal to 5.5 mEq/L AND 2) Documentation that member is taking Kerendia in combination with an ACEi or ARB at maximum tolerated doses or documentation has been provided that the member is unable to tolerate ACEi or ARB. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

KEVZARA

Products Affected

- KEVZARA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Specialist for submitted diagnosis. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | For RA: Either 1) Trial of, medical reason for not using, or contraindication to 2 of the following: Enbrel, Humira, Hadlima, Rinvoq or Xeljanz or 2) If utilized within the past 120 days, approve for continuation of therapy. For polymyalgia rheumatica (PMR): Trial of, medical reason for not using, or contraindication to corticosteroids. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

KINERET

Products Affected

- KINERET SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Specialist for submitted diagnosis. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | For RA: Either 1) Trial of, medical reason for not using, or contraindication to 2 of the following: Enbrel, Humira, Hadlima, Rinvoq or Xeljanz or 2) If utilized within the past 120 days, approve for continuation of therapy. For cryopyrin-associated periodic syndromes or deficiency of interleukin-1 receptor antagonist: Approve. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

KORLYM

Products Affected

- KORLYM
- *mifepristone oral tablet 300 mg*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | For all members patient must not be currently on simvastatin, lovastatin, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus. |
| Required Medical Information | Reviewer will verify available claim history to confirm member is not taking simvastatin, lovastatin, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus or tacrolimus concurrently with Korlym. |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be an endocrinologist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

LITFULO

Products Affected

- LITFULO

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Documentation was submitted indicating that the member was evaluated for active or latent TB infection (i.e. tuberculin skin test) |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | Documentation of confirmed diagnosis and other causes of hair loss have been ruled out. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

LIVMARLI

Products Affected

- LIVMARLI

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with a gastroenterologist or hepatologist. |
| Coverage Duration | New starts will be authorized for 6 months. Cont of therapy or reauth until end of contract year. |
| Other Criteria | For new starts: 1) Trial of, contraindication to, or medical reason for not using both of the following: cholestyramine AND rifampin. 2) Prescriber attests that the member has cholestasis 3) Baseline serum bile acid level is provided. 4) Documentation of patients weight. For continuation of therapy or reauthorization: 1) Documentation submitted indicating the member has had all of the following: an improvement in pruritis (e.g. improved observed scratching, decreased sleep disturbances/nighttime awakenings due to scratching, etc.) AND reduction in serum bile acid level from baseline. 2) Prescriber attests that patient has had no evidence of hepatic decompensation (e.g. variceal hemorrhage, ascites, hepatic encephalopathy, portal hypertension, etc.). 3) Documentation of patients weight. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

LODOCO

Products Affected

- LODOCO

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be, or in consultation with a specialist in the treatment of cardiovascular disease, such as a cardiologist |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | Documentation that patient has established atherosclerotic disease or multiple risk factors for cardiovascular disease AND documentation that patient does not have pre-existing blood dyscrasias (ex. leukopenia, thrombocytopenia) and patient does not have renal failure (CrCl less than 15 ml/min) or severe hepatic impairment |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

LUCEMYRA

Products Affected

- LUCEMYRA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized for 14 days. |
| Other Criteria | For new starts, patient must have trial of, contraindication to, or medical reason for not using clonidine. Reauthorization criteria: chart notes that show positive response to prior treatment. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

LUPKYNIS

Products Affected

- LUPKYNIS

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Concurrent use with cyclophosphamide. |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be rheumatologist, nephrologist, or other specialist in the treatment of autoimmune disorders. |
| Coverage Duration | New starts will be authorized for 6 months. Cont of therapy or reauth until end of contract year. |
| Other Criteria | For new starts: 1) Documentation of urine protein/creatinine ratio (UPCR), 2) Documentation that the member has a baseline eGFR greater than 45 mL/min/1.73m ² or that benefit outweighs risk of using this medication at current eGFR, and 3) Concurrent use of or medical reason for not using background immunosuppressive therapy regimen. For continuation of therapy or reauthorization: Documentation of improvement in renal function (i.e. reduction in UPCR or no confirmed decrease from baseline eGFR greater than or equal to 20%). |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

100

LYBALVI

Products Affected

- LYBALVI

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Concomitant use with opioids. |
| Required Medical Information | Attestation from the provider that the member has had an opioid-free period of a minimum of 7 days after last use of shorting-acting opioids and 14 days from last use of long-acting opioids before initiating Lybalvi. |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | Documented trial of, contraindication to, or medical reason for not using at least two generic antipsychotics, one of which must be generic olanzapine. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

MANNITOL INHALATION

Products Affected

- BRONCHITOL

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a pulmonologist or an expert in the treatment of cystic fibrosis. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

MAVYRET

Products Affected

- MAVYRET

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Detectable HCV RNA viral load prior to treatment within 6 months of request. In addition, documentation of treatment history, and if cirrhotic, documentation of compensated or decompensated cirrhosis. |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized for 8-16 weeks as per AASLD-IDSA guidance. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

METHYLTESTOSTERONE

Products Affected

- *methyltestosterone oral*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

METYROSIINE

Products Affected

- *metyrosine*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Documentation of one of the following: 1) Concurrent use of alpha adrenergic blockers, 2) Medical reason for being unable to use an alpha adrenergic blocker, OR 3) Patient is not a candidate for surgical resection and requires long term treatment with metyrosine. |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

MIGLUSTAT

Products Affected

- *miglustat*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | For new starts, documentation of diagnosis for mild to moderate type 1 Gaucher disease. For continuation of therapy or reauthorization: documentation of clinical benefit from use of the drug (i.e. increased platelet count, improvement in anemia, PFT's, improvement in radiographic scans, improved quality of life). |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with a specialist in treatment of Gaucher's disease |
| Coverage Duration | New starts will be authorized for 6 months. Cont of therapy or reauth until end of contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

MULTIPLE SCLEROSIS AGENTS

Products Affected

- BAFIERTAM
- BETASERON SUBCUTANEOUS KIT
- *dimethyl fumarate oral*
- *dimethyl fumarate starter pack oral capsule delayed release therapy pack*
- EXTAVIA SUBCUTANEOUS KIT
- *fingolimod hcl*
- *glatiramer acetate*
- *glatopa*
- KESIMPTA
- MAVENCLAD (10 TABS)
- MAVENCLAD (4 TABS)
- MAVENCLAD (5 TABS)
- MAVENCLAD (6 TABS)
- MAVENCLAD (7 TABS)
- MAVENCLAD (8 TABS)
- MAVENCLAD (9 TABS)
- MAYZENT
- MAYZENT STARTER PACK
- PONVORY
- PONVORY STARTER PACK
- REBIF REBIDOSE SUBCUTANEOUS SOLUTION AUTO-INJECTOR
- REBIF REBIDOSE TITRATION PACK SUBCUTANEOUS SOLUTION AUTO-INJECTOR
- REBIF SUBCUTANEOUS SOLUTION PREFILLED SYRINGE
- REBIF TITRATION PACK SUBCUTANEOUS SOLUTION PREFILLED SYRINGE
- TASCENSO ODT
- *teriflunomide*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Specialist for submitted diagnosis. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | If the medication request is for glatiramer, Glatopa, or dimethyl fumarate, the request will be approved. If the member is over 17 years of age and the request is not for glatiramer, Glatopa, or dimethyl fumarate for multiple sclerosis, the member must have a documented trial of, contraindication to or a medical reason for not using both dimethyl fumarate AND glatiramer |

Formulary ID 24425

Last Updated: 03/2024

| PA Criteria | Criteria Details |
|----------------------------|--|
| | or Glatopa. If the request is for fingolimod and the member is 17 years of age or younger, the request will be approved. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

MYFEMBREE

Products Affected

- MYFEMBREE

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Patient has history of osteoporosis or hepatic impairment. |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be an OB, gynecologist or reproductive endocrinologist. |
| Coverage Duration | New starts will be authorized for 6 months. Cont of therapy or reauth until end of contract year. |
| Other Criteria | For new starts for menorrhagia: Trial of, contraindication to, or medical reason for not using an estrogen-progestin contraceptive therapy. For new starts if one of the following drugs has been tried previously, a trial of estrogen-progestin contraceptive therapy is not required: gonadotropin-releasing hormone (GnRH) agonists or tranexamic acid. New starts for endometriosis: Trial of, contraindication to, or medical reason for not using the following concurrently for endometriosis: analgesic pain reliever (e.g. NSAIDs, COX-2 inhibitors) AND either combined estrogen-progestin oral contraceptive, progestin (e.g. medroxyprogesterone acetate, norethindrone), gonadotropin-releasing hormone (GnRH) agonists (e.g. Lupron Depot), OR danazol. For continuation of therapy or reauthorization both of the following are required: 1) Treatment does not exceed the eligible maximum lifetime treatment duration of 2 years, and 2) Documentation has been provided that the member has obtained clinical benefit from medication (e.g. reduced menstrual bleeding from baseline, pain relief). |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

NASAL ANTISEIZURE AGENTS

Products Affected

- NAYZILAM
- VALTOCO 10 MG DOSE
- VALTOCO 15 MG DOSE
- VALTOCO 20 MG DOSE
- VALTOCO 5 MG DOSE

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with a neurologist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

NATPARA

Products Affected

- NATPARA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Documentation of serum calcium greater than 7.5 mg/dL and vitamin D level (within 30 days of request). |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber is an endocrinologist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

NEXLETOL

Products Affected

- NEXLETOL

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a cardiologist, endocrinologist, or a specialist in treatment of lipid disorders. |
| Coverage Duration | New starts will be authorized for 4 months. Cont of therapy or reauth until end of contract year. |
| Other Criteria | For new starts ALL of the following must be provided: 1) Documentation of baseline low density lipoprotein cholesterol (LDL-C) 2) Member has tried and failed a high-intensity statin (i.e. atorvastatin 40-80 mg, rosuvastatin 20-40 mg) at maximum tolerated dose for 3 months via claim history or chart notes OR documentation has been provided that the member is not able to tolerate a statin 3) Member has tried and failed ezetimibe at a maximum tolerated dose or documentation has been provided that the patient is not able to tolerate ezetimibe AND 4) Member will continue on maximum tolerated statin dose and ezetimibe dose while receiving Nexletol or documentation has been provided that the member is not able to tolerate a statin and/or ezetimibe. In addition to the initial criteria above if the new start is for the diagnosis of hyperlipidemia and atherosclerotic cardiovascular disease (ASCVD), the following are required: 1) Documentation of history of at least one of the following: myocardial infarction or acute coronary syndrome, stroke or transient ischemic attack, coronary artery disease with stable angina, coronary or other arterial revascularization, peripheral vascular disease, or aortic aneurysm AND 2) Member must have a fasting LDL-C greater than or equal to 70 mg/dL. For continuation of therapy or reauthorization requests for all indications: 1) Documentation provided that the member has obtained clinical benefit from medication (e.g. LDL-C lowering from |

Formulary ID 24425

Last Updated: 03/2024

| PA Criteria | Criteria Details |
|----------------------------|---|
| | baseline) AND 2) Member will continue on maximum tolerated statin and ezetimibe dose while receiving Nexletol or documentation has been provided that the member is not able to tolerate a statin and/or ezetimibe. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

NEXLIZET

Products Affected

- NEXLIZET

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a cardiologist, endocrinologist, or a specialist in treatment of lipid disorders. |
| Coverage Duration | New starts will be authorized for 4 months. Cont of therapy or reauth until end of contract year. |
| Other Criteria | For new starts ALL of the following must be provided: 1) Documentation of baseline low density lipoprotein cholesterol (LDL-C), 2) Member has tried and failed a high-intensity statin (i.e. atorvastatin 40-80 mg, rosuvastatin 20-40 mg) at maximum tolerated dose for 3 months via claim history or chart notes OR documentation has been provided that the member is not able to tolerate a statin, AND 3) Member will continue on maximum tolerated statin dose while receiving Nexlizet or documentation has been provided that the member is not able to tolerate a statin. In addition to the initial criteria above if the new start is for the diagnosis of hyperlipidemia and atherosclerotic cardiovascular disease (ASCVD), the following are required: 1) Documentation of history of at least one of the following: myocardial infarction or acute coronary syndrome, stroke or transient ischemic attack, coronary artery disease with stable angina, coronary or other arterial revascularization, peripheral vascular disease, or aortic aneurysm, AND 2) Member must have a fasting LDL-C greater than or equal to 70 mg/dL. For continuation of therapy or reauthorization requests for all indications: 1) Documentation provided that the member has obtained clinical benefit from medication (e.g. LDL-C lowering from baseline), AND 2) Member will continue on maximum tolerated statin while receiving Nexlizet or documentation has been provided that the member is not able to tolerate a statin. |

Formulary ID 24425

Last Updated: 03/2024

| PA Criteria | Criteria Details |
|----------------------------|-------------------------------------|
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

NITISINONE

Products Affected

- *nitisinone*
- ORFADIN ORAL SUSPENSION

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a geneticist, metabolic specialist, hepatologist, or liver transplant specialist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

NON-AMPHETAMINE CENTRAL NERVOUS SYSTEM AGENTS

Products Affected

- *armodafinil*
- *modafinil oral*

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

NUCALA

Products Affected

- NUCALA

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Specialist for submitted diagnosis. |
| Coverage Duration | New starts will be authorized for 6 months. Cont of therapy or reauth until end of contract year. |
| Other Criteria | New starts for severe asthma: 1) Baseline blood eosinophil count greater than or equal to 150 cells per microliter AND 2) symptoms with equal to or greater than 1 exacerbations in the previous 12 months requiring additional medical treatment, (e.g. oral systemic steroids) while on a high-dose inhaled corticosteroid with an additional controller medication (ie. long-acting B2 agonist). New starts for eosinophilic granulomatosis with polyangiitis (EGPA): trial of, contraindication to, or medical reason for not using one of the following medications: cyclophosphamide or methotrexate. New starts for hypereosinophilic syndrome without an identifiable non-hematologic secondary cause: 1) 2 or more flares within the past 12 months AND 2) trial of, contraindication to, or medical reason for not using oral corticosteroids. New starts for chronic rhinosinusitis with nasal polyps: trial of, contraindication to, or medical reason for not using nasal corticosteroids OR member has had prior surgery for nasal polyps. Continuation of therapy or re-authorization for all indications: clinical benefit from use of the drug. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

Formulary ID 24425

Last Updated: 03/2024

| PA Criteria | Criteria Details |
|--------------------------------|-------------------------|
| Part B Prerequisite | No |

NUEDEXTA

Products Affected

- NUEDEXTA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Complete atrioventricular (AV) block without implanted pacemaker, or at high risk of complete AV block. History of heart failure. Concomitant use with MAOIs or use of MAOIs within 14 days. Concomitant use with drugs containing quinidine, quinine, or mefloquine. History of quinine-, mefloquine-, dextromethorphan/quinidine-, or quinidine-induced thrombocytopenia, hepatitis, bone marrow depression, or lupus-like syndrome. Non-Part D indications. |
| Required Medical Information | Confirmation diagnosis is for Part D indication. |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with a neurologist or psychiatrist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

120

NUPLAZID

Products Affected

- NUPLAZID ORAL CAPSULE
- NUPLAZID ORAL TABLET 10 MG

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

OCALIVA

Products Affected

- OCALIVA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Members with decompensated cirrhosis, a prior decompensation event, compensated cirrhosis who have evidence of portal hypertension, or complete biliary obstruction. |
| Required Medical Information | For new starts: 1) Attestation that the member has failed at least a 12 month trial of ursodiol, or has a medical reason (e.g. intolerance, hypersensitivity) for being unable to tolerate ursodiol AND 2) lab results for baseline ALT/AST, alkaline phosphatase (ALP), and bilirubin within 90 days of request. For continuation of therapy or reauthorization: Documentation that that the member has responded to Ocaliva (e.g. improved biochemical markers (e.g., ALP, bilirubin, GGT, AST, ALT levels)). |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a gastroenterologist, hepatologist, or transplant specialist. |
| Coverage Duration | New starts will be authorized for 6 months. Cont of therapy or reauth until end of contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

OCTREOTIDE

Products Affected

- *octreotide acetate injection solution 100 mcg/ml, 1000 mcg/ml, 200 mcg/ml, 50 mcg/ml, 500 mcg/ml*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | For new starts for acromegaly: pt meets one of the following (1) inadequate response to surgery and/or radiotherapy OR (2) pt is not an appropriate candidate for surgery and/or radiotherapy OR (3) pt is experiencing negative effects due to tumor size (ex: optic nerve compression). Continuation of therapy or reauthorization: documentation of clinical improvement with therapy. |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | Continuation of therapy or reauthorization: documentation of clinical improvement with therapy. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

OFEV

Products Affected

- OFEV

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a pulmonologist or lung transplant specialist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | For a diagnosis of idiopathic pulmonary fibrosis: 1) Documentation of disease as demonstrated on a high resolution CT scan or through lung biopsy and 2) Documented trial of, contraindication to, or medical reason for not using pirfenidone. For a diagnosis of systemic sclerosis-associated interstitial lung disease (SSc-ILD): documented trial of, contraindication to, or medical reason for not using mycophenolate mofetil or cyclophosphamide. For a diagnosis of chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype: documentation is provided confirming diagnosis. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

OLUMIANT

Products Affected

- OLUMIANT

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Specialist for submitted diagnosis. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | For RA: Either 1) Trial of, medical reason for not using, or contraindication to 2 of the following: Enbrel, Humira, Hadlima, Rinvoq, or Xeljanz, or 2) If utilized within the past 120 days, approve for continuation of therapy. For alopecia areata: Documentation of confirmed diagnosis and other causes of hair loss have been ruled out. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

ORAL ANTINEOPLASTIC AGENTS

Products Affected

- *abiraterone acetate*
- AKEEGA
- ALECENSA
- ALUNBRIG
- AUGTYRO
- AYVAKIT
- BALVERSA
- *bexarotene*
- BOSULIF
- BRAFTOVI ORAL CAPSULE 75 MG
- BRUKINSA
- CABOMETYX
- CALQUENCE
- CAPRELSA
- COMETRIQ (100 MG DAILY DOSE)
ORAL KIT 80 & 20 MG
- COMETRIQ (140 MG DAILY DOSE)
ORAL KIT 3 X 20 MG & 80 MG
- COMETRIQ (60 MG DAILY DOSE)
- COPIKTRA
- COTELLIC
- DAURISMO
- ERIVEDGE
- ERLEADA
- *erlotinib hcl*
- *everolimus oral tablet 10 mg, 2.5 mg, 5 mg, 7.5 mg*
- *everolimus oral tablet soluble*
- EXKIVITY
- FOTIVDA
- FRUZAQLA
- GAVRETO
- *gefitinib*
- GILOTRIF
- IBRANCE
- ICLUSIG
- IDHIFA
- *imatinib mesylate*
- IMBRUVICA
- INLYTA
- INQOVI
- INREBIC
- IWILFIN
- JAYPIRCA
- KISQALI (200 MG DOSE)
- KISQALI (400 MG DOSE)
- KISQALI (600 MG DOSE)
- KISQALI FEMARA (200 MG DOSE)
- KISQALI FEMARA (400 MG DOSE)
- KISQALI FEMARA (600 MG DOSE)
- KOSELUGO
- KRAZATI
- *lapatinib ditosylate*
- *lenalidomide*
- LENVIMA (10 MG DAILY DOSE)
- LENVIMA (12 MG DAILY DOSE)
- LENVIMA (14 MG DAILY DOSE)
- LENVIMA (18 MG DAILY DOSE)
- LENVIMA (20 MG DAILY DOSE)
- LENVIMA (24 MG DAILY DOSE)
- LENVIMA (4 MG DAILY DOSE)
- LENVIMA (8 MG DAILY DOSE)
- LONSURF
- LORBRENA
- LUMAKRAS
- LYNPARZA ORAL TABLET
- LYTGOBI (12 MG DAILY DOSE)
- LYTGOBI (16 MG DAILY DOSE)
- LYTGOBI (20 MG DAILY DOSE)
- MEKINIST
- MEKTOVI
- NERLYNX
- *nilutamide*
- NINLARO
- NUBEQA
- ODOMZO
- OGSIVEO
- OJJAARA
- ONUREG
- ORGOVYX
- ORSERDU
- *pazopanib hcl*

Formulary ID 24425

Last Updated: 03/2024

- PEMAZYRE
- PIQRAY (200 MG DAILY DOSE)
- PIQRAY (250 MG DAILY DOSE)
- PIQRAY (300 MG DAILY DOSE)
- POMALYST
- PURIXAN
- QINLOCK
- RETEVMO
- REVLIMID
- REZLIDHIA
- ROZLYTREK
- RUBRACA
- RYDAPT
- SCEMBLIX
- SOLTAMOX
- *sorafenib tosylate*
- SPRYCEL
- STIVARGA
- *sunitinib malate*
- TABLOID
- TABRECTA
- TAFINLAR
- TAGRISSO
- TALZENNA
- TASIGNA
- TAZVERIK
- TEPMETKO
- THALOMID
- TIBSOVO
- *toremifene citrate*
- *tretinoin oral*
- TRUQAP
- TRUSELTIQ (100MG DAILY DOSE)
- TRUSELTIQ (125MG DAILY DOSE)
- TRUSELTIQ (50MG DAILY DOSE)
- TRUSELTIQ (75MG DAILY DOSE)
- TUKYSA
- TURALIO
- VANFLYTA
- VENCLEXTA
- VENCLEXTA STARTING PACK
- VERZENIO
- VITRAKVI
- VIZIMPRO
- VONJO
- WELIREG
- XALKORI
- XOSPATA
- XPOVIO (100 MG ONCE WEEKLY)
ORAL TABLET THERAPY PACK 50
MG
- XPOVIO (40 MG ONCE WEEKLY)
ORAL TABLET THERAPY PACK 40
MG
- XPOVIO (40 MG TWICE WEEKLY)
ORAL TABLET THERAPY PACK 40
MG
- XPOVIO (60 MG ONCE WEEKLY)
ORAL TABLET THERAPY PACK 60
MG
- XPOVIO (60 MG TWICE WEEKLY)
- XPOVIO (80 MG ONCE WEEKLY)
ORAL TABLET THERAPY PACK 40
MG
- XPOVIO (80 MG TWICE WEEKLY)
- XTANDI
- YONSA
- ZEJULA
- ZELBORAF
- ZOLINZA
- ZYDELIG
- ZYKADIA ORAL TABLET

| PA Criteria | Criteria Details |
|---------------------------|------------------|
| Exclusion Criteria | N/A |

Formulary ID 24425

Last Updated: 03/2024

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be an oncologist or specialist for submitted diagnosis. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024
128

ORAL ANTIPSYCHOTICS

Products Affected

- CAPLYTA
- FANAPT
- FANAPT TITRATION PACK
- VRAYLAR ORAL CAPSULE
- VRAYLAR ORAL CAPSULE THERAPY PACK

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | For schizophrenia and manic or mixed episodes associated with bipolar I disorder and major depressive disorder associated with bipolar I or II disorder: trial of, contraindication to, or medical reason for not using two generic antipsychotics. If the request is for Vraylar for major depressive disorder: provider attestation that the member is concurrently using an antidepressant. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

ORENCIA

Products Affected

- ORENCIA CLICKJECT
- ORENCIA INTRAVENOUS
- ORENCIA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Specialist for submitted diagnosis. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | For pJIA: Either 1) Trial of, medical reason for not using, or contraindication to 2 of the following: Enbrel, Humira, Hadlima, or Xeljanz or 2) If utilized within the past 120 days, approve for continuation of therapy. For PsA: Either 1) Trial of, medical reason for not using, or contraindication to 2 of the following therapies: Stelara, Skyrizi, Tremfya, Xeljanz, Rinvoq, Enbrel, Hadlima, or Humira, or 2) If utilized within the past 120 days, approve for continuation of therapy. For RA: Either 1) Trial of, medical reason for not using, or contraindication to 2 of the following: Enbrel, Humira, Hadlima, Rinvoq or Xeljanz or 2) If utilized within the past 120 days, approve for continuation of therapy. For acute graft versus host disease: Attestation member is taking in combination with a calcineurin inhibitor and methotrexate. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

ORIAHNN

Products Affected

- ORIAHNN

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Patient has history of osteoporosis or hepatic impairment. |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be an OB, gynecologist or reproductive endocrinologist. |
| Coverage Duration | New starts will be authorized for 6 months. Cont of therapy or reauth until end of contract year. |
| Other Criteria | For new starts: Trial of, contraindication to, or medical reason for not using an estrogen-progestin contraceptive therapy. For new starts if one of the following drugs has been tried previously, a trial of estrogen-progestin contraceptive therapy is not required: gonadotropin-releasing hormone (GnRH) agonists or tranexamic acid. For continuation of therapy or reauthorization both of the following are required: 1) Treatment does not exceed the eligible maximum lifetime treatment duration of 2 years, and 2) Documentation has been provided that the member has obtained clinical benefit from medication (e.g. reduced menstrual bleeding from baseline). |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

ORILISSA

Products Affected

- ORILISSA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Patient has osteoporosis or severe hepatic impairment. |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be an OB or gynecologist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | Trial of, contraindication to, or medical reason for not using the following concurrently for endometriosis: analgesic pain reliever (e.g. NSAIDs, COX-2 inhibitors) AND either combined estrogen-progestin oral contraceptive, progestin (e.g. medroxyprogesterone acetate, norethindrone), gonadotropin-releasing hormone (GnRH) agonists (e.g. Lupron Depot), OR danazol. For continuation of therapy or reauthorization both of the following are required: 1) Treatment does not exceed the eligible maximum lifetime treatment duration of 2 years for 150mg tablet or 6 months for 200mg tablet, and 2) Documentation has been provided that the member has obtained clinical benefit from the medication. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

ORKAMBI

Products Affected

- ORKAMBI

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Combination use with Kalydeco, Symdeko, or Trikafta. |
| Required Medical Information | Documentation of CFTR gene that is responsive to lumacaftor-ivacaftor treatment. |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a pulmonologist or an expert in the treatment of cystic fibrosis. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

OTEZLA

Products Affected

- OTEZLA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Specialist for submitted diagnosis. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | For moderate to severe psoriasis: Either 1) Trial of, medical reason for not using, or contraindication to 2 of the following therapies: Stelara, Skyrizi, Tremfya, Enbrel, Hadlima, or Humira, or 2) If utilized within the past 120 days, approve for continuation of therapy. For PsA: Either 1) Trial of, medical reason for not using, or contraindication to 2 of the following therapies: Stelara, Skyrizi Tremfya, Xeljanz, Rinvoq, Enbrel, Hadlima, or Humira, or 2) If utilized within the past 120 days, approve for continuation of therapy. For Behcet's Syndrome or mild psoriasis: Approve. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

OXBRYTA

Products Affected

- OXBRYTA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | New starts: Documentation is provided for all of the following: 1) baseline labs: Hemoglobin (Hb) level less than 10.5 g/dL, indirect bilirubin, and reticulocytes, 2) member has had 1 or more pain crises in the last 12 months, and 3) member has been taking hydroxyurea at the maximum tolerated dose (or a medical reason was provided why the patient is unable to use hydroxyurea). Continuation of therapy or reauthorization at 6 months from initiation and at subsequent 12-month intervals: Documentation of 1 of the following: 1) Hb increase from baseline (at 6 months from initiation) or maintenance of such Hb increase (at 12-month intervals thereafter), or 2) reduced number of vaso-occlusive/pain crises since Oxbryta was started, or 3) decrease in indirect bilirubin from baseline, or decrease in percentage of reticulocytes from baseline. |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a hematologist. |
| Coverage Duration | New starts will be authorized for 6 months. Cont of therapy or reauth until end of contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

OXERVATE

Products Affected

- OXERVATE

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be an ophthalmologist. |
| Coverage Duration | Request will be authorized for 8 weeks. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

OXYCODONE ER

Products Affected

- *oxycodone hcl er oral tablet er 12 hour abuse-deterrent 10 mg, 20 mg, 40 mg*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | Members being treated for active cancer diagnoses, sickle cell diagnoses, those in hospice care, or receiving palliative care will be excluded from the concurrent benzodiazepine and muscle relaxant therapy requirement. For new starts, ALL of the following are required: (1) Member has documented history of receiving an immediate-release opioid, (2) Member has a documented trial of, contraindication to, or medical reason for not using long-acting morphine sulfate, (3) If member is on concurrent benzodiazepines and/or muscle relaxant therapy, the prescriber attests that concurrent therapy is medically necessary, (4) Member is not being treated for substance abuse with buprenorphine-containing products. For continuing therapy, ALL of the following are required: (1) Member's pain has been assessed within the last 6 months, (2) Member has demonstrated clinical improvement in pain and function on current medication regimen, (3) If member is on concurrent benzodiazepines and/or muscle relaxant therapy, the prescriber attests that concurrent therapy is medically necessary, (4) Member is not being treated for substance abuse with buprenorphine-containing products. |
| Indications | All Medically-accepted Indications. |

Formulary ID 24425

Last Updated: 03/2024

| PA Criteria | Criteria Details |
|----------------------------|-------------------------|
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024
138

PALIPERIDONE INJECTABLE

Products Affected

- INVEGA SUSTENNA
INTRAMUSCULAR SUSPENSION
PREFILLED SYRINGE 117 MG/0.75ML,
156 MG/ML, 234 MG/1.5ML, 39
MG/0.25ML, 78 MG/0.5ML
- INVEGA TRINZA INTRAMUSCULAR
SUSPENSION PREFILLED SYRINGE
273 MG/0.88ML, 410 MG/1.32ML, 546
MG/1.75ML, 819 MG/2.63ML

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | The member has a documented history of receiving oral risperidone or oral paliperidone without any clinically significant side effects. For requests for Invega Trinza, the member has documented treatment with Invega Sustenna for at least 4 months. |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | Trial of, contraindication to, or medical reason for not using Abilify Maintena. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

PALIPERIDONE ORAL

Products Affected

- *paliperidone er oral tablet extended release 24 hour 1.5 mg, 3 mg, 6 mg, 9 mg*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | For schizophrenia: trial of, contraindication to, or medical reason for not using an alternative generic second generation atypical antipsychotic. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

PCSK9 INHIBITORS

Products Affected

- PRALUENT SUBCUTANEOUS SOLUTION AUTO-INJECTOR
- REPATHA
- REPATHA PUSHTRONEX SYSTEM
- REPATHA SURECLICK

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a cardiologist, endocrinologist, or a specialist in treatment of lipid disorders. |
| Coverage Duration | New starts will be authorized for 4 months. Cont of therapy or reauth until end of contract year. |
| Other Criteria | For ALL diagnoses (including primary hyperlipidemia) for new starts, attestations of the following: 1) Two fasting lipid panel reports within the past 12 months with abnormal LDL cholesterol results (above 70mg/dL) after treatment for a minimum of 3 months with two high potency statins (atorvastatin and rosuvastatin) or a medical reason (contraindication or intolerance) has been provided as to why the patient is unable to use these therapies, and 2) If patient experiences statin intolerance, trial of statin re-challenge with maximally tolerated dose of statins with continued abnormal LDL cholesterol results (above 70mg/dL) or with attestation of return of side effects. For familial hypercholesterolemia (FH), attestation of TWO of the following: 1) genetic testing confirming FH diagnosis, 2) clinical manifestations of FH such as xanthomas or inflamed tendons, 3) a clinical diagnosis of FH using the Dutch Lipid Clinic Diagnostic criteria (total score greater than 8 points), OR Simon-Broome Diagnostic criteria (total cholesterol greater than 290 mg/dL or LDL-C greater than 190 mg/dL, plus tendon xanthoma in patient, first-degree parent, sibling or child) or second-degree relative (grandparent, uncle or aunt). For ASCVD, additional attestation of history of acute coronary syndromes, history of MI, stable or unstable angina, coronary or other arterial revascularization, stroke, TIA, or peripheral arterial disease presumed to be of atherosclerotic |

Formulary ID 24425

Last Updated: 03/2024

| | |
|----------------------------|---|
| PA Criteria | Criteria Details |
| | origin. For ALL diagnoses for continuation of therapy or reauthorization: attestation of improvement in LDL from new start. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

PEGINTERFERON

Products Affected

- PEGASYS SUBCUTANEOUS SOLUTION 180 MCG/ML
- PEGASYS SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | For Hepatitis C: 1) Labs within 3 months of request: liver function tests and detectable HCV RNA viral load. 2) Documentation of genotype, treatment history, and if cirrhotic, documentation of compensated or decompensated cirrhosis. For Hepatitis B: 1) Labs within 3 months of request: ALT/AST, and 2) HBeAg status. For polycythemia vera, approve. |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a gastroenterologist, hepatologist, infectious disease doctor or transplant specialist. |
| Coverage Duration | Request will be authorized for 24 to 48 weeks as defined by compendia. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

PENICILLAMINE

Products Affected

- *penicillamine oral tablet*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Specialist for submitted diagnosis. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | For RA: Trial of, medical reason for not using, or contraindication to 2 of the following: Enbrel, Humira, Hadlima, Rinvoq or Xeljanz. For other indications, approve. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

PENTAMIDINE SOLUTION FOR INJECTION

Products Affected

- *pentamidine isethionate injection*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

PERSERIS

Products Affected

- PERSERIS

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | The member has a documented history of receiving oral risperidone without any clinically significant side effects. |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | Trial of, contraindication to, or medical reason (e.g. intolerance, hypersensitivity or contraindication) for not using Abilify Maintena |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

PHENOXYBENZAMINE

Products Affected

- *phenoxybenzamine hcl oral*

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | Trial of, contraindication to, or medical reason for not using doxazosin. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

PIRFENIDONE

Products Affected

- *pirfenidone*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | For idiopathic pulmonary fibrosis, documentaton of all of the following: 1) confirmation of diagnosis on high resolution CT scan or through lung biopsy AND 2) FVC greater than or equal to 50% of the predicted value. |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a pulmonologist or lung transplant specialist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

148

POSACONAZOLE

Products Affected

- *posaconazole oral*

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Documentation of a consultation with an infectious disease specialist, a transplant specialist, or an oncologist. |
| Coverage Duration | 28 days for oropharyngeal candidiasis, end of contract year for other indications |
| Other Criteria | For treatment of oropharyngeal candidiasis: trial of, contraindication to, or medical reason for not using fluconazole or itraconazole. For prophylaxis of invasive aspergillus infections due to being severely immunocompromised: trial of, contraindication to, or medical reason for not using voriconazole. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

PRETOMANID

Products Affected

- PRETOMANID

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | MDR-TB that is not treatment-intolerant or nonresponsive to standard therapy |
| Required Medical Information | Documentation of use in combination with bedaquiline and linezolid. |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with an infectious disease specialist. |
| Coverage Duration | Request will be authorized for 26 weeks. |
| Other Criteria | Documentation of prior trial of or medical reason for not using first-line TB regimen containing isoniazid and rifampin. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

PREVYMIS

Products Affected

- PREVYMIS ORAL

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a hematologist, oncologist, infectious disease, or transplant specialist. |
| Coverage Duration | Request will be authorized for 6 months. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

PROLIA

Products Affected

- PROLIA SUBCUTANEOUS SOLUTION
PREFILLED SYRINGE

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | For new starts for a diagnosis of osteoporosis: Documentation showing patient falls into one of the following categories: Postmenopausal woman or a male patient who has a bone mineral density (BMD) value consistent with osteoporosis (i.e., T-scores equal to or less than - 2.5) or who has had an osteoporotic fracture. Postmenopausal woman or man with a T-score between -1 and -2.5 at the femoral neck or spine and a 10 year hip fracture probability greater than 3% or a 10 year major osteoporosis-related fracture probability greater than 20% based on the US-adapted WHO absolute fracture risk model. For continuation of therapy or reauthorization: Prescriber attests that patient has clinically benefited from medication. |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | The following criteria is also applicable for new starts: trial of, contraindication to, or medical reason for not using an oral bisphosphonate. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024
152

PROMACTA

Products Affected

- PROMACTA ORAL PACKET 12.5 MG, 25 MG
- PROMACTA ORAL TABLET 12.5 MG, 25 MG, 50 MG, 75 MG

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | For chronic immune (idiopathic) thrombocytopenia (ITP): Documented baseline platelet count less than 30,000 cells/ microL. For severe aplastic anemia: Documentation of baseline platelet count less than 20,000 cells/microL OR platelet count less than 30,000 cells/microL with bleeding OR reticulocyte count less than 20,000 cells/microL OR absolute neutrophil count less than 500 cells/microL. For thrombocytopenia in patients with Hepatitis C infection: documented baseline platelet count less than 75,000 cells/microL. |
| Age Restrictions | N/A |
| Prescriber Restrictions | Specialist for submitted diagnosis. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | For chronic immune (idiopathic) thrombocytopenia (ITP): Trial of, contraindication to, or medical reason for not using glucocorticosteroids. For severe aplastic anemia: Trial of, contraindication to, or medical reason for not using at least one immunosuppressive agent. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

PYRUKYND

Products Affected

- PYRUKYND
- PYRUKYND TAPER PACK

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | For new starts: 1) documentation of diagnosis and 2) baseline hemoglobin level. For continuation of therapy or reauthorization: documentation of clinical improvement (e.g. reduction in number of blood transfusions, or increase or stabilization in hemoglobin level). If the criteria are not met, may authorize up to 14 days of a Pyrukynd Taper Pack to allow for tapering. |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with a hematologist. |
| Coverage Duration | New starts: 6 mo. Cont of therapy or reauth: end of contract yr. Denial: 14 days for dose tapering. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

RADICAVA

Products Affected

- RADICAVA ORS
- RADICAVA ORS STARTER KIT

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a neurologist. |
| Coverage Duration | New starts: 6 months. Cont. of therapy or reauthorization: until end of contract year. |
| Other Criteria | For new starts: 1) documentation of ALS functional rating scale (ALSFRS-R) score and 2) documentation that the member has been on riluzole, is beginning therapy as an adjunct to treatment with Radicava, or provider has provided a medical reason why patient is unable to use riluzole. For continuation of therapy or reauthorization: documentation from provider of clinical stabilization in symptoms (e.g. stabilization of ALS functional rating scale (ALSFRS-R) score). |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

RAVICTI

Products Affected

- RAVICTI

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Provider is a geneticist, metabolic specialist, gastroenterologist, hepatologist, or liver transplant specialist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | Trial of, contraindication to, or medical reason for not using sodium phenylbutyrate. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

RECORLEV

Products Affected

- RECORLEV

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Specialist for submitted diagnosis. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | Trial of, contraindication to, or medical reason for not using ketoconazole tablets. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

REGRANEX

Products Affected

- REGRANEX

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized for 20 weeks. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

RELISTOR

Products Affected

- RELISTOR ORAL
- RELISTOR SUBCUTANEOUS SOLUTION

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | Patient must have documented trial of or medical reason for not using the following: 1) lubiprostone, AND 2) lactulose AND 3) Movantik. Additionally, patient must have a medical reason for not being able to use oral Relistor in order to receive Relistor injection. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

RELYVRIO

Products Affected

- RELYVRIO

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | For new starts: Documentation of diagnosis of ALS. For continuation of therapy or reauthorization: Documentation or provider attestation of positive clinical response (such as improvement in the Revised ALS Functional Rating Scale (ALSFRS-R) total score) |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with a neurologist, neuromuscular specialist, or physician specializing in the treatment of amyotrophic lateral sclerosis. |
| Coverage Duration | New starts: 6 months. Cont. of therapy or reauthorization: until end of contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

160

REXULTI

Products Affected

- REXULTI

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | For schizophrenia: trial of, contraindication to, or medical reason for not using two generic antipsychotics. For major depressive disorder: trial of, contraindication to, or medical reason for not using to two generic antidepressants. For agitation associated with dementia: approve. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

REZUROCK

Products Affected

- REZUROCK

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a hematologist, oncologist, or transplant specialist. |
| Coverage Duration | New starts: 3 months. Cont. of therapy or reauthorization: until end of contract year. |
| Other Criteria | For new starts: documented trial of, contraindication to, or medical reason for not using at least two lines of systemic immunosuppressive therapy (e.g. corticosteroids, tacrolimus, mycophenolate mofetil, Imbruvica, or Jakafi), one of which must be a systemic corticosteroid. For continuation of therapy or re-authorization: documentation of clinical benefit from use of the drug (i.e. symptom improvement, reduction in corticosteroid dose). |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

RINVOQ

Products Affected

- RINVOQ

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Specialist for submitted diagnosis. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | For RA: Trial of, medical reason for not using, or contraindication to 1 disease modifying antirheumatic drug (DMARD) (methotrexate, leflunomide, or sulfasalazine) and 1 tumor necrosis factor (TNF) blocker (Enbrel, Hadlima, or Humira). For PsA: Trial of, medical reason for not using, or contraindication to 1 TNF blocker (Enbrel, Hadlima, or Humira). For atopic dermatitis: trial of, contraindication to, or medical reason for not using: 1) topical tacrolimus or pimecrolimus and 2) Eucrisa. For ankylosing spondylitis: Trial of, medical reason for not using, or contraindication to naproxen and 1 TNF blocker (Enbrel, Hadlima, or Humira). For UC: Trial of, medical reason for not using, or contraindication to 1 of the following conventional therapies: mercaptopurine, an aminosalicylate (i.e. mesalamine, sulfasalazine, azathioprine), or a corticosteroid (i.e. prednisone, methylprednisolone) and Humira, or Hadlima. For non-radiographic axial spondyloarthritis: Trial of, medical reason for not using, or contraindication to naproxen. For Crohns Disease: trial of, medical reason for not using, or contraindication to 1 TNF blocker. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

Formulary ID 24425

Last Updated: 03/2024

| PA Criteria | Criteria Details |
|--------------------------------|-------------------------|
| Part B Prerequisite | No |

RISPERIDONE INJECTABLE

Products Affected

- *risperidone microspheres er*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | The member has a documented history of receiving oral risperidone without any clinically significant side effects. |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | Trial of, contraindication to, or medical reason (e.g. intolerance, hypersensitivity or contraindication) for not using Abilify Maintena. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

RUFINAMIDE

Products Affected

- *rufinamide oral suspension*
- *rufinamide oral tablet*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | History of familial Short QT syndrome |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a neurologist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | Trial of, contraindication to, or medical reason for not using one alternative generic anticonvulsant for appropriate indications. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

RYKINDO

Products Affected

- RYKINDO

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | The member has a documented history of receiving oral risperidone without any clinically significant side effects. |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | Trial of, contraindication to, or medical reason (e.g. intolerance, hypersensitivity or contraindication) for not using Abilify Maintena. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

RYLAZE

Products Affected

- RYLAZE

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be an oncologist, hematologist, or specialist for submitted diagnosis. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

168

SAPROPTERIN

Products Affected

- *sapropterin dihydrochloride oral packet*
- *sapropterin dihydrochloride oral tablet*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | For new starts: documentation of elevated baseline phenylalanine levels. Continuation of therapy or reauthorization: prescriber attests the member has improvement in phenylalanine levels from baseline. |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | New starts will be authorized for 3 months. Cont of therapy or reauth until end of contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

SECUADO

Products Affected

- SECUADO

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | Trial of, contraindication to, or medical reason for not using to one generic antipsychotics. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

170

SEROSTIM

Products Affected

- SEROSTIM SUBCUTANEOUS SOLUTION RECONSTITUTED 4 MG, 5 MG, 6 MG

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with a HIV specialist, gastroenterologist, nutritional support specialist or ID specialist. |
| Coverage Duration | Request will be authorized for 12 weeks. |
| Other Criteria | For initial starts for HIV wasting/cachexia: 1) Member must be on anti-retroviral therapy and 2) Trial of, contraindication to or medical reason for not using megestrol or dronabinol and 3) Alternative causes of wasting have been ruled out (diarrhea, malignancies, inadequate caloric intake, etc) |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

SIGNIFOR

Products Affected

- SIGNIFOR

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Member is not a candidate for surgery or surgery was not curative. |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with an endocrinologist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

172

SILDENAFIL ORAL

Products Affected

- *sildenafil citrate oral suspension reconstituted*
- *sildenafil citrate oral tablet 20 mg*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Documentation of concurrent nitrate or Adempas use. |
| Required Medical Information | Documentation of pulmonary arterial hypertension (PAH) WHO Group I and PAH Functional Class. Reviewer will verify available patient claim history to confirm patient is not using nitrates or Adempas. |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a pulmonologist or cardiologist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | For sildenafil suspension: Documentation of trial of, contraindication to, or medical reason for not using sildenafil tablet. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

SILIQ

Products Affected

- SILIQ

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Specialist for submitted diagnosis. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | For psoriasis: Either 1) Trial of, medical reason for not using, or contraindication to 2 of the following therapies: Stelara, Skyrizi, Tremfya, Enbrel, Hadlima, or Humira, or 2) If utilized within the past 120 days, approve for continuation of therapy. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

SIMPONI

Products Affected

- SIMPONI SUBCUTANEOUS SOLUTION AUTO-INJECTOR
- SIMPONI SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Specialist for submitted diagnosis. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | For ankylosing spondylitis: Either 1) Trial of, medical reason for not using, or contraindication to 2 of the following therapies: Enbrel, Humira, Hadlima, Rinvoq or Xeljanz, or 2) If utilized within the past 120 days, approve for continuation of therapy. For PsA: Either 1) Trial of, medical reason for not using, or contraindication to 2 of the following therapies: Stelara, Skyrizi, Tremfya, Xeljanz, Rinvoq, Enbrel, Hadlima, or Humira, or 2) If utilized within the past 120 days, approve for continuation of therapy. For RA: Either 1) Trial of, medical reason for not using, or contraindication to 2 of the following: Enbrel, Humira, Hadlima, Rinvoq or Xeljanz or 2) If utilized within the past 120 days, approve for continuation of therapy. For UC: Either 1) Trial of, medical reason for not using, or contraindication to 2 of the following: Humira, Hadlima, Rinvoq, Stelara or Xeljanz or 2) If utilized within the past 120 days, approve for continuation of therapy. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

SIRTURO

Products Affected

- SIRTURO

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Documentation (consistent with pharmacy claims data, OR for new members to the health plan consistent with medical chart history) that the member is currently taking 3 additional antimycobacterial drugs in combination to treat MDR-TB. |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with an infectious disease specialist. |
| Coverage Duration | Request will be authorized for 24 weeks. |
| Other Criteria | Documentation of prior trial of or medical reason for not using first-line TB regimen containing isoniazid and rifampin. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

SKYRIZI

Products Affected

- SKYRIZI
- SKYRIZI PEN

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Specialist for submitted diagnosis. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | For PsA or psoriasis: approve. For Crohns Disease: Either 1) Trial of, medical reason for not using (i.e. severe Crohns disease), or contraindication to 1 of the following: mercaptopurine, azathioprine, sulfasalazine, methotrexate or corticosteroid (e.g., prednisone, methylprednisolone) or 2) If utilized within the past 120 days, approve for continuation of therapy. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

SODIUM PHENYL BUTYRATE

Products Affected

- *sodium phenylbutyrate oral powder 3 gm/tsp*
- *sodium phenylbutyrate oral tablet*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Provider is a geneticist, metabolic specialist, gastroenterologist, hepatologist, or liver transplant specialist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

SOFOSBUVIR/VELPATASVIR

Products Affected

- SOFOSBUVIR-VELPATASVIR

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Detectable HCV RNA viral load prior to treatment within 6 months of request. In addition, documentation of treatment history, and if cirrhotic, documentation of compensated or decompensated cirrhosis. |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized for 12-24 weeks based on AASLD-IDSA guidelines |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

SOMAVERT

Products Affected

- SOMAVERT

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | For new starts for acromegaly: pt meets one of the following (1) inadequate response to surgery and/or radiotherapy OR (2) pt is not an appropriate candidate for surgery and/or radiotherapy OR (3) pt is experiencing negative effects due to tumor size (ex: optic nerve compression). Continuation of therapy or reauthorization: documentation of clinical improvement with therapy. |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with an endocrinologist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

180

SOTYKTU

Products Affected

- SOTYKTU

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Specialist for submitted diagnosis. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | For moderate to severe psoriasis: Either 1) Trial of, medical reason for not using, or contraindication to 2 of the following therapies: Stelara, Skyrizi, Tremfya, Enbrel, Hadlima, or Humira, or 2) If utilized within the past 120 days, approve for continuation of therapy. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

STELARA

Products Affected

- STELARA INTRAVENOUS
- STELARA SUBCUTANEOUS SOLUTION 45 MG/0.5ML
- STELARA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Specialist for submitted diagnosis. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | For Crohns Disease: Either 1) Trial of, medical reason for not using (i.e. severe Crohns disease), or contraindication to 1 of the following: mercaptopurine, azathioprine, methotrexate, sulfasalazine, or corticosteroid (e.g., prednisone, methylprednisolone) or 2) If utilized within the past 120 days, approve for continuation of therapy. For psoriasis: Approve. For PsA: Approve. For UC: Either 1) Trial of, medical reason for not using, or contraindication to 1 of the following conventional therapies: mercaptopurine, an aminosalicilate (i.e. mesalamine, sulfasalazine, azathioprine), or a corticosteroid (i.e. prednisone, methylprednisolone) or 2) If utilized within the past 120 days, approve for continuation of therapy. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024
182

SUCRAID

Products Affected

- SUCRAID

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | For new starts: documentation of diagnosis of congenital sucrase-isomaltase deficiency. For continuation of therapy or reauthorization: Prescriber attests that member has obtained a clinical benefit (e.g. fewer total stools, greater number of hard and formed stools, fewer watery and soft stools, decrease in breath hydrogen output) |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | New starts will be authorized for 3 months. Cont of therapy or reauth until end of contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

SYMDEKO

Products Affected

- SYMDEKO

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Combination use with Kalydeco, Orkambi, or Trikafta. |
| Required Medical Information | Documentation of CFTR gene that is responsive to tezacaftor-ivacaftor treatment. |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a pulmonologist or an expert in the treatment of cystic fibrosis. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

SYMLIN

Products Affected

- SYMLINPEN 120 SUBCUTANEOUS SOLUTION PEN-INJECTOR
- SYMLINPEN 60 SUBCUTANEOUS SOLUTION PEN-INJECTOR

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Patient has confirmed gastroparesis. |
| Required Medical Information | For new starts: HbA1C values within 90 days of request is greater than or equal to 7% despite receiving insulin therapy. |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | Trial of, contraindication to, or medical reason for not using two alternative anti-diabetic agents. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

SYNAREL

Products Affected

- SYNAREL

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | Trial of, contraindication to, or medical reason for not using the following concurrently for endometriosis: analgesic pain reliever (e.g. NSAIDs, COX-2 inhibitors) AND either combined estrogen-progestin oral contraceptive, progestin (e.g. medroxyprogesterone acetate, norethindrone), OR gonadotropin-releasing hormone (GnRH) agonists (e.g. Lupron Depot) |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

186

TADALAFIL

Products Affected

- *tadalafil (pah)*
- TADLIQ

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Documentation of concurrent nitrate or Adempas use. |
| Required Medical Information | Documentation of pulmonary arterial hypertension (PAH) WHO Group I and PAH Functional Class. Reviewer will verify available patient claim history to confirm patient is not using nitrates or Adempas. |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a pulmonologist or cardiologist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | For Tadliq: Documentation of trial of, contraindication to, or medical reason for not using tadalafil tablets. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

TALTZ

Products Affected

- TALTZ

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Specialist for submitted diagnosis. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | For ankylosing spondylitis: Either 1) Trial of, medical reason for not using, or contraindication to 2 of the following therapies: Enbrel, Humira, Hadlima, Rinvoq or Xeljanz, or 2) If utilized within the past 120 days, approve for continuation of therapy. For non-radiographic axial spondyloarthritis: approve. For psoriasis: Either 1) Trial of, medical reason for not using, or contraindication (e.g., safety concerns, not indicated for patient's age) to 2 of the following therapies: Stelara, Skyrizi, Tremfya, Enbrel, Hadlima, or Humira, or 2) If utilized within the past 120 days, approve for continuation of therapy. For PsA: Either 1) Trial of, medical reason for not using, or contraindication to 2 of the following therapies: Stelara, Skyrizi, Tremfya, Xeljanz, Rinvoq, Enbrel, Hadlima, or Humira, or 2) If utilized within the past 120 days, approve for continuation of therapy. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

188

TARPEYO

Products Affected

- TARPEYO

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | For new starts: attestation that member has 1) Diagnosis of primary immunoglobulin A nephropathy (IgAN) and 2) at risk of rapid disease progression. Member has an estimated glomerular filtration rate (eGFR) greater than or equal to 35 mL/min/1.73 m(2) and proteinuria. For continuation of therapy: documentation that member has been on Tarpeyo for less than 9 months. For reauthorizations: Requests will not be allowed as the safety and efficacy of subsequent courses of Tarpeyo have not been established. |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with a nephrologist. |
| Coverage Duration | Request will be authorized for 9 months. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

TAVNEOS

Products Affected

- TAVNEOS

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with a rheumatologist or hematologist. |
| Coverage Duration | New starts will be authorized for 6 months. Cont of therapy or reauth until end of contract year. |
| Other Criteria | For new starts: 1) Prescriber attests that Tavneos will be prescribed in combination with corticosteroids AND cyclophosphamide unless there is documented trial of, contraindication to, or medical reason for not using these therapies. 2) Documentation of baseline Birmingham Vasculitis Activity Score (BVAS) score 3) Prescriber attestation that the patient will have liver function tests before treatment (ALT, AST, alkaline phosphate, and total bilirubin) and every 4 weeks after start of therapy for the first 6 months of treatment 4) Prescriber attestation that the patient has been screened for and does not have active hepatitis B virus (HBV) infection at baseline. For continuation of therapy or reauthorization: 1) Documentation of remission (BVAS score of 0) OR improvement in BVAS score 2) Prescriber attestation that patient has no abnormality in liver function tests (abnormality: ALT or AST greater than 3 times the upper limit of normal and bilirubin greater than 2 times the upper limit of normal) 3) Prescriber attestation that patient has no active HBV infection. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

TEFLARO

Products Affected

- TEFLARO

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Documentation of a consultation with an infectious disease specialist. |
| Coverage Duration | Request will be authorized for 14 days. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

TERIPARATIDE

Products Affected

- *teriparatide*
- *teriparatide (recombinant) subcutaneous solution pen-injector 600 mcg/2.4ml*
- TERIPARATIDE (RECOMBINANT) SUBCUTANEOUS SOLUTION PEN-INJECTOR 620 MCG/2.48ML

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Documentation showing patient falls into one of the following categories: Postmenopausal woman who has a bone mineral density (BMD) value consistent with osteoporosis (i.e., T-scores equal to or less than -2.5) or postmenopausal woman who has had an osteoporotic fracture. Postmenopausal woman who has T-scores from -1.5 to -2.5 and at least one of the following risk factors for fracture: thinness [low body mass index (less than 21 kg/m ²)], history of fragility fracture since menopause, or history of hip fracture in a parent. Male greater than or equal to 65 years of age with T-score of -2.5 or less. Male less than 65 years of age with T-score of -2.5 or less and 2 or more risk factors for fractures or previous osteoporotic fracture. |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | In addition, the following criteria is also applicable: 1) Trial of, medical reason for not using, or contraindication to an oral bisphosphonate and Prolia and 2) therapy does not exceed the therapy maximum of 2 years. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

THIOLA

Products Affected

- THIOLA EC
- *tiopronin oral*

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

TOLVAPTAN

Products Affected

- *tolvaptan*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Concomitant use with strong CYP3A4 inhibitors (i.e. clarithromycin, ketoconazole, itraconazole, ritonavir, lopinavir-ritonavir, indinavir-ritonavir, indinavir, nelfinavir, saquinavir, nefazodone, conivaptan, and telithromycin). |
| Required Medical Information | Reviewer will verify available patient claim history to confirm patient is not using a strong CYP3A4 inhibitor (i.e. clarithromycin, ketoconazole, itraconazole, ritonavir, lopinavir-ritonavir, indinavir-ritonavir, indinavir, nelfinavir, saquinavir, nefazodone, conivaptan, and telithromycin). |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with a cardiologist, endocrinologist, hepatologist, or nephrologist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

TOPICAL ANTINEOPLASTIC RETINOIDS

Products Affected

- *bexarotene*
- PANRETIN

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

TOPICAL TESTOSTERONE

Products Affected

- *testosterone transdermal gel 1.62 %, 12.5 mg/act (1%), 20.25 mg/1.25gm (1.62%), 20.25 mg/act (1.62%), 25 mg/2.5gm (1%), 40.5 mg/2.5gm (1.62%), 50 mg/5gm (1%)*
- *testosterone transdermal solution*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Patient has history of prostate cancer or breast cancer. |
| Required Medical Information | New starts of topical testosterone therapy for hypogonadism must have both of the following characteristics of hypogonadism: 1) symptoms associated with hypogonadism (e.g. unexplained mild anemia, low libido, decreased energy, etc.) 2) Two separate instances of low serum total or free testosterone taken in the morning, as defined by the lab reference range. |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

TRANSDERMAL LIDOCAINE

Products Affected

- *lidocaine external patch 5 %*
- ZTLIDO

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | If the request is for the product ZTlido, must provide medical reason for not being able to use generic lidocaine 5% patch |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

TREMFYA

Products Affected

- TREMFYA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Specialist for submitted diagnosis. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | For PsA or psoriasis: approve. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024
198

TRIENTINE

Products Affected

- CUVRIOR
- *trientine hcl oral capsule 250 mg*

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | If the request is for Cuvrior for new starts, member must have trial of, contraindication to, or medical reason for not using trientine hydrochloride. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

TRIKAFTA

Products Affected

- TRIKAFTA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Combination use with Kalydeco, Orkambi, or Symdeko. |
| Required Medical Information | Documentation of CFTR gene that is responsive to elexacaftor-tezacaftor-ivacaftor treatment. |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a pulmonologist or an expert in the treatment of cystic fibrosis. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024
200

TYMLOS

Products Affected

- TYMLOS

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Documentation showing patient falls into one of the following categories: a bone mineral density (BMD) value consistent with osteoporosis (i.e., T-scores equal to or less than -2.5) or patient has had an osteoporotic fracture or patient has T-scores from -1.5 to -2.5 at the femoral neck or spine, and a 10-year probability of hip fracture greater than or equal to 3% or a 10-year probability of any major osteoporosis-related fracture greater than or equal to 20% based on the United States-adapted FRAX model. |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | The following criteria is also applicable: 1) trial of, contraindication to, or medical reason for not using an oral bisphosphonate and Prolia, and 2) therapy does not exceed 2 years. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

TYVASO

Products Affected

- TYVASO DPI MAINTENANCE KIT
- TYVASO DPI TITRATION KIT
INHALATION POWDER 16 & 32 & 48
MCG

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a pulmonologist or cardiologist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | For the treatment of pulmonary arterial hypertension (PAH): 1) documentation of PAH WHO Group I classification and PAH Functional Class and 2) trial of, contraindication to, or medical reason for not using a generic phosphodiesterase inhibitor and a generic endothelin receptor antagonist. For the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD, WHO Group 3): documentation of PH-ILD and PAH Functional Class. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024
202

UPTRAVI

Products Affected

- UPTRAVI ORAL
- UPTRAVI TITRATION

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Documentation of pulmonary arterial hypertension (PAH) WHO Group I and PAH Functional Class. |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a pulmonologist or cardiologist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | Trial of, contraindication to, or medical reason for not using a generic phosphodiesterase inhibitor and a generic endothelin receptor antagonist. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

UZEDY

Products Affected

- UZEDY

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | The member has a documented history of receiving oral risperidone without any clinically significant side effects. |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | Trial of, contraindication to, or medical reason (e.g. intolerance, hypersensitivity or contraindication) for not using Abilify Maintena. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

204

VALCHLOR

Products Affected

- VALCHLOR

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with an oncologist or dermatologist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | Trial of, contraindication to, or medical reason for not being able to use one of the following: a topical corticosteroids or a topical retinoids. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

VEMLIDY

Products Affected

- VEMLIDY

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | For new starts: attestation that member has been tested for HIV infection. If member is HIV-positive, Vemlidy is not used alone. |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024
206

VENTAVIS

Products Affected

- VENTAVIS

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Documentation of pulmonary arterial hypertension (PAH) WHO Group I classification and PAH Functional Class. |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a pulmonologist or cardiologist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

VIGABATRIN

Products Affected

- *vigabatrin*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | For infantile spasms or West syndrome, the request will be approved. For diagnosis of refractory complex partial seizures: 1) documentation of diagnosis, and 2) attestation the member is currently receiving another antiepileptic drug, and 3) attestation the member has experienced treatment failure from two generic alternative formulary antiepileptic agents. |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a neurologist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

208

VIJOICE

Products Affected

- VIJOICE

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | For new starts, all of the following must be included: 1) Documentation of genetic testing confirming diagnosis AND 2) Member has at least one target lesion identified on imaging AND 3) Prescriber attests the patient's condition is severe or life-threatening and necessitates systemic treatment. For continuation of therapy or reauthorization, attestation of a positive clinical response (i.e. reduction in the sum of measurable target lesion volume, absence of progression of non-target lesions, absence of any new lesions, etc.). |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with a geneticist, dermatologist, vascular surgeon, hematologist/oncologist, or other specialist in the treatment of PIK3CA-Related Overgrowth Spectrum(PROOS). |
| Coverage Duration | New starts will be authorized for 6 months. Cont of therapy or reauth until end of contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

VMAT-2 INHIBITORS

Products Affected

- AUSTEDO
- AUSTEDO PATIENT TITRATION KIT
- INGREGZA ORAL CAPSULE
- INGREGZA ORAL CAPSULE THERAPY PACK
- *tetrabenazine*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a neurologist, clinical geneticist, or psychiatrist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | If the request is for tetrabenazine, request will be approved. If the request is for Ingrezza and Austedo, the member must have trial of or medical reason for not using the tetrabenazine. Reauthorization: Confirmation of improvement in tardive dyskinesia symptoms or chorea associated with Huntington disease symptoms. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

VORICONAZOLE

Products Affected

- *voriconazole intravenous*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Non-Part D indications. |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized for 6 months. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

VOSEVI

Products Affected

- VOSEVI

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Detectable HCV RNA viral load prior to treatment within 6 months of request. In addition, documentation of treatment history, and if cirrhotic, documentation of compensated or decompensated cirrhosis. |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized for 12 weeks as per AASLD-IDSA guidance. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

212

VOWST

Products Affected

- VOWST

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Treatment of Clostridioides difficile infection (CDI) |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | If all the criteria are met, the request will be approved for 1 month |
| Other Criteria | Diagnosis of at least 1 recurrent episode of CDI |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

WHITE BLOOD CELL STIMULATORS

Products Affected

- FULPHILA
- FYLNETRA
- LEUKINE INJECTION SOLUTION RECONSTITUTED
- NEULASTA ONPRO
- NEULASTA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE
- NYVEPRIA
- UDENYCA
- UDENYCA ONBODY
- ZARXIO
- ZIEXTENZO

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | For new starts for Neulasta, Fulphila, Udenyca and Nyvepria: documentation of trial of, contraindication to, or medical reason for not using Fylnetra and Ziextenzo. Continuation of therapy or re-authorization criteria: diagnosis of chronic neutropenia or a medical reason for continued need for GCSF. |
| Age Restrictions | N/A |
| Prescriber Restrictions | Specialist for submitted diagnosis. |
| Coverage Duration | New starts will be authorized for 4 months. Cont of therapy or reauth until end of contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

XATMEP

Products Affected

- XATMEP

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be an oncologist or rheumatologist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

XELJANZ

Products Affected

- XELJANZ
- XELJANZ XR

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Specialist for submitted diagnosis. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | For ankylosing spondylitis: Trial of, medical reason for not using, or contraindication to naproxen and 1 TNF blocker (Enbrel, Hadlima, or Humira) For pJIA: Trial of, medical reason for not using, or contraindication to 1 of the following DMARDs: methotrexate or leflunomide and 1 TNF blocker (Enbrel, Hadlima, or Humira). For PsA: Trial of, medical reason for not using, or contraindication to 1 TNF blocker (Enbrel, Hadlima, or Humira). For RA: Trial of, medical reason for not using, or contraindication to 1 disease modifying antirheumatic drug (DMARD) (methotrexate, leflunomide, or sulfasalazine) and 1 tumor necrosis factor (TNF) blocker (Enbrel, Hadlima, or Humira). For UC: Trial of, medical reason for not using, or contraindication to 1 of the following conventional therapies: mercaptopurine, an aminosalicilate (i.e. mesalamine, sulfasalazine, azathioprine), or a corticosteroid (i.e. prednisone, methylprednisolone) and Humira or Hadlima. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

XERMELO

Products Affected

- XERMELO

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with a gastroenterologist or an oncologist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | For new starts: 1) Attestation that diarrhea is inadequately controlled by stable dose of SSA therapy for at least three months. For continuation of therapy or reauthorization: 1) documentation of positive clinical response to xermelo and 2) Attestation to continue to be used in combination with SSA. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

XGEVA

Products Affected

- XGEVA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Patients with baseline hypocalcemia |
| Required Medical Information | New starts: Serum calcium levels. Reauthorization criteria for malignant hypercalcemia: albumin-adjusted serum calcium level below 12.5mg/dl within 30 days of request. |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

218

XIFAXAN

Products Affected

- XIFAXAN

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | For HE: gastroenterologist or hepatologist. For IBS-D: gastroenterologist. |
| Coverage Duration | For HE: contract year. For IBSD: 14 days (cannot exceed 3 courses of 14 days each). For TD: 3 days. |
| Other Criteria | For diagnosis of hepatic encephalopathy (HE): trial of, contraindication to, or medical reason for not using lactulose. For diagnosis of irritable bowel syndrome with diarrhea (IBSD): No more than 3 courses of 14 days each. For travelers diarrhea (TD) caused by noninvasive strains of E. Coli (with no bloody stools or fever): patient must be intolerant to or must have had a trial of at least 3 days of one of the following agents: ciprofloxacin, ofloxacin, levofloxacin or azithromycin. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

XOLAIR

Products Affected

- XOLAIR

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a pulmonologist, allergist, immunologist, dermatologist, or otolaryngologist. |
| Coverage Duration | New starts will be authorized for 6 months. Cont of therapy or reauth until end of contract year. |
| Other Criteria | New starts for moderate to severe persistent allergic asthma: 1) Evidence of specific allergic sensitivity confirmed by positive skin test (i.e. prick/puncture test) or blood test (i.e. radioallergosorbent test) for a specific IgE or in vitro reactivity to a perennial aeroallergen, AND 2) Pretreatment serum IgE levels greater than 30 IU/mL, AND 3) Symptoms are not adequately controlled with high-dose inhaled corticosteroid (ICS) plus additional controller medication (ie. long-acting B2 agonist) for at least 3 months, or there is a medical reason for not using these drugs. Continuation of therapy or reauthorization criteria for moderate to severe persistent allergic asthma: 1) Reduction in asthma exacerbation resulting in systemic steroid use and/or hospitalization, OR 2) Reduction of rescue inhaler use, OR 3) Documentation of improvement in pulmonary function tests since baseline (prior to initiation of Xolair). New starts for chronic idiopathic urticaria: 1) inadequate symptomatic relief despite trial of two weeks of two different oral antihistamine therapies (unless contraindicated), AND 2) disease must be severe enough to warrant short term systemic corticosteroid therapy for management of urticaria. Continuation of therapy or reauthorization criteria for chronic idiopathic urticaria: 1) improvement from baseline of symptoms associated with urticaria within 6 months of Xolair use. New starts for nasal polyps: 1) currently using an intranasal corticosteroid, will be prescribed an intranasal corticosteroid with request, |

Formulary ID 24425

Last Updated: 03/2024

220

| PA Criteria | Criteria Details |
|----------------------------|--|
| | <p>or has a medical reason for not using an intranasal corticosteroid. Continuation of therapy or reauthorization criteria for nasal polyps: 1) Documentation has been provided that demonstrates a clinical benefit (e.g. improvements in symptom severity, nasal polyp score [NPS], sino-nasal outcome test-22 [SNOT-22], nasal congestion score [NCS]) AND 2) continued use of intranasal corticosteroid, or has a medical reason for not using one.</p> |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

XURIDEN

Products Affected

- XURIDEN

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be an endocrinologist, metabolic specialist, clinical geneticist or hematologist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

222

XYREM

Products Affected

- *sodium oxybate*
- XYREM

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a sleep specialist, pulmonologist, or neurologist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | For somnolence associated with narcolepsy: trial of, contraindication to, or medical reason for not using a CNS stimulant (e.g. methylphenidate, modafinil, armodafinil, etc.). For cataplexy associated with narcolepsy, approve. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

XYWAV

Products Affected

- XYWAV

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a sleep specialist, pulmonologist or a neurologist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | For treatment of somnolence associated with narcolepsy, patient must have documentation of either trial of or a medical reason for being unable to use a CNS stimulant (e.g. methylphenidate, modafinil, armodafinil, etc.). For the treatment of cataplexy associated with narcolepsy or idiopathic hypersomnia, approve. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

224

ZEPOSIA

Products Affected

- ZEPOSIA
- ZEPOSIA 7-DAY STARTER PACK
- ZEPOSIA STARTER KIT ORAL CAPSULE THERAPY PACK 0.23MG & 0.46MG 0.92MG(21)

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Specialist for submitted diagnosis. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | For multiple sclerosis: Trial of, contraindication to, or medical reason for not using both dimethyl fumarate AND glatiramer or Glatopa. For ulcerative colitis: Either 1) Trial of, medical reason for not using, or contraindication Humira or Hadlima or 2) If utilized within the past 120 days, approve for continuation of therapy. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

ZILBRYSQ

Products Affected

- ZILBRYSQ

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a neurologist, rheumatologist, or other appropriate specialist |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | Patient has tried and failed, a medical reason for not using, or has a contraindication to two (2) or more conventional therapies (i.e. pyridostigmine, corticosteroids, or non-steroidal immunosuppressive therapies) |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

226

ZTALMY

Products Affected

- ZTALMY

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with a neurologist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

ZURZUVAE

Products Affected

- ZURZUVAE

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | The member has a documented diagnosis of postpartum depression |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with a psychiatrist or obstetrician/gynecologist |
| Coverage Duration | Request will be authorized until the end of the contract year |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

Formulary ID 24425

Last Updated: 03/2024

228

ZYPREXA RELPREVV

Products Affected

- ZYPREXA RELPREVV RECONSTITUTED 210 MG, 300 MG,
INTRAMUSCULAR SUSPENSION 405 MG

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | The member has a documented history of receiving oral olanzapine without any clinically significant side effects. |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | Trial of, contraindication to, or medical reason for not using Abilify Maintena. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

PART B VERSUS PART D

Products Affected

- ABELCET INTRAVENOUS SUSPENSION 5 MG/ML
- *acetylcysteine inhalation solution 10 %, 20 %*
- *acyclovir sodium intravenous solution 50 mg/ml*
- *albuterol sulfate inhalation nebulization solution (2.5 mg/3ml) 0.083%, (5 mg/ml) 0.5%, 0.63 mg/3ml, 1.25 mg/3ml, 2.5 mg/0.5ml*
- *amphotericin b intravenous solution reconstituted 50 mg*
- *amphotericin b liposome intravenous suspension reconstituted 50 mg*
- *aprepitant oral 80 & 125 mg*
- *aprepitant oral capsule 125 mg, 40 mg, 80 & 125 mg, 80 mg*
- ASTAGRAF XL ORAL CAPSULE EXTENDED RELEASE 24 HOUR 0.5 MG, 1 MG, 5 MG
- *azathioprine oral tablet 50 mg*
- *budesonide inhalation suspension 0.25 mg/2ml, 0.5 mg/2ml, 1 mg/2ml*
- *clinisol sf intravenous solution 15 %*
- *cromolyn sodium inhalation nebulization solution 20 mg/2ml*
- *cyclophosphamide oral capsule 25 mg, 50 mg*
- *cyclophosphamide oral tablet 25 mg, 50 mg*
- *cyclosporine modified oral capsule 100 mg, 25 mg, 50 mg*
- *cyclosporine modified oral solution 100 mg/ml*
- *cyclosporine oral capsule 100 mg, 25 mg*
- DIPHTHERIA-TETANUS TOXOIDS DT INTRAMUSCULAR SUSPENSION 25-5 LFU/0.5ML
- *dronabinol oral capsule 10 mg, 2.5 mg, 5 mg*
- EMEND ORAL SUSPENSION RECONSTITUTED 125 MG/5ML
- ENGERIX-B INJECTION SUSPENSION 20 MCG/ML
- ENGERIX-B INJECTION SUSPENSION PREFILLED SYRINGE 10 MCG/0.5ML, 20 MCG/ML
- ENVARSUS XR ORAL TABLET EXTENDED RELEASE 24 HOUR 0.75 MG, 1 MG, 4 MG
- *everolimus oral tablet 0.25 mg, 0.5 mg, 0.75 mg, 1 mg*
- *formoterol fumarate inhalation nebulization solution 20 mcg/2ml*
- GAMMAGARD INJECTION SOLUTION 1 GM/10ML, 10 GM/100ML, 2.5 GM/25ML, 20 GM/200ML, 30 GM/300ML, 5 GM/50ML
- GAMMAGARD S/D LESS IGA INTRAVENOUS SOLUTION RECONSTITUTED 10 GM, 5 GM
- GAMMAKED INJECTION SOLUTION 1 GM/10ML
- GAMMAPLEX INTRAVENOUS SOLUTION 10 GM/100ML, 10 GM/200ML, 20 GM/200ML, 5 GM/50ML
- GAMUNEX-C INJECTION SOLUTION 1 GM/10ML
- *gengraf oral capsule 100 mg, 25 mg*
- *gengraf oral solution 100 mg/ml*
- *granisetron hcl oral tablet 1 mg*
- HEPLISAV-B INTRAMUSCULAR SOLUTION PREFILLED SYRINGE 20 MCG/0.5ML
- IMOVAX RABIES INTRAMUSCULAR SUSPENSION RECONSTITUTED 2.5 UNIT/ML
- INTRALIPID INTRAVENOUS EMULSION 20 %, 30 %
- *ipratropium bromide inhalation solution 0.02 %*

Formulary ID 24425

Last Updated: 03/2024
230

- *ipratropium-albuterol inhalation solution 0.5-2.5 (3) mg/3ml*
- *levalbuterol hcl inhalation nebulization solution 0.31 mg/3ml, 0.63 mg/3ml, 1.25 mg/3ml*
- *mycophenolate mofetil oral capsule 250 mg*
- *mycophenolate mofetil oral suspension reconstituted 200 mg/ml*
- *mycophenolate mofetil oral tablet 500 mg*
- *mycophenolate sodium oral tablet delayed release 180 mg, 360 mg*
- *mycophenolic acid oral tablet delayed release 180 mg, 360 mg*
- NULOJIX INTRAVENOUS SOLUTION RECONSTITUTED 250 MG
- NUTRILIPID INTRAVENOUS EMULSION 20 %
- *ondansetron hcl oral solution 4 mg/5ml*
- *ondansetron hcl oral tablet 24 mg, 4 mg, 8 mg*
- *ondansetron oral tablet dispersible 4 mg, 8 mg*
- *pentamidine isethionate inhalation solution reconstituted 300 mg*
- *plenamine intravenous solution 15 %*
- PREHEVBRIO INTRAMUSCULAR SUSPENSION 10 MCG/ML
- PRIVIGEN INTRAVENOUS SOLUTION 10 GM/100ML, 20 GM/200ML, 40 GM/400ML, 5 GM/50ML
- PROGRAF INTRAVENOUS SOLUTION 5 MG/ML
- PROGRAF ORAL PACKET 0.2 MG, 1 MG
- PULMOZYME INHALATION SOLUTION 2.5 MG/2.5ML
- RABA VERT INTRAMUSCULAR SUSPENSION RECONSTITUTED
- RECOMBIVAX HB INJECTION SUSPENSION 10 MCG/ML, 40 MCG/ML, 5 MCG/0.5ML
- RECOMBIVAX HB INJECTION SUSPENSION PREFILLED SYRINGE 10 MCG/ML, 5 MCG/0.5ML
- SANDIMMUNE ORAL SOLUTION 100 MG/ML
- *sirolimus oral solution 1 mg/ml*
- *sirolimus oral tablet 0.5 mg, 1 mg, 2 mg*
- *tacrolimus oral capsule 0.5 mg, 1 mg, 5 mg*
- TDVAX INTRAMUSCULAR SUSPENSION 2-2 LF/0.5ML
- TENIVAC INTRAMUSCULAR INJECTABLE 5-2 LFU, 5-2 LFU (INJECTION)
- TETANUS-DIPHThERIA TOXOIDS TD INTRAMUSCULAR SUSPENSION 2-2 LF/0.5ML
- *tobramycin inhalation nebulization solution 300 mg/5ml*

Details

This drug may be covered under Medicare Part B or D depending upon the circumstances. Information may need to be submitted describing the use and setting of the drug to make the determination.

Index

A

ABELCET INTRAVENOUS
SUSPENSION 5 MG/ML..... 230
ABILIFY ASIMTUFII..... 1
abiraterone acetate 126, 127, 128
acetylcysteine inhalation solution 10 %, 20
% 230
acitretin..... 2
ACTEMRA ACTPEN..... 3
ACTEMRA SUBCUTANEOUS 3
ACTHAR 4
ACTIMMUNE..... 5
acyclovir sodium intravenous solution 50
mg/ml 230
ADEMPAS..... 6
AIMOVIG 24, 25
AKEEGA 126, 127, 128
albuterol sulfate inhalation nebulization
solution (2.5 mg/3ml) 0.083%, (5 mg/ml)
0.5%, 0.63 mg/3ml, 1.25 mg/3ml, 2.5
mg/0.5ml..... 230
ALECENSA 126, 127, 128
ALUNBRIG 126, 127, 128
ambrisentan 8
amitriptyline hcl oral 76
amoxapine 76
amphotericin b intravenous solution
reconstituted 50 mg 230
amphotericin b liposome intravenous
suspension reconstituted 50 mg..... 230
apomorphine hcl subcutaneous 9
aprepitant oral 80 & 125 mg 230
aprepitant oral capsule 125 mg, 40 mg, 80 &
125 mg, 80 mg 230
ARALAST NP INTRAVENOUS
SOLUTION RECONSTITUTED 1000
MG, 500 MG 7
ARANESP (ALBUMIN FREE)
INJECTION SOLUTION 100 MCG/ML,
200 MCG/ML, 25 MCG/ML, 40
MCG/ML, 60 MCG/ML 52

ARANESP (ALBUMIN FREE)
INJECTION SOLUTION PREFILLED
SYRINGE 52
ARCALYST..... 10
ARISTADA INITIO 11
ARISTADA INTRAMUSCULAR
PREFILLED SYRINGE 1064
MG/3.9ML, 441 MG/1.6ML, 662
MG/2.4ML, 882 MG/3.2ML 11
armodafinil 117
ascomp-codeine 77
ASTAGRAF XL ORAL CAPSULE
EXTENDED RELEASE 24 HOUR 0.5
MG, 1 MG, 5 MG 230
AUGTYRO 126, 127, 128
AUSTEDO 210
AUSTEDO PATIENT TITRATION KIT
..... 210
AUVELITY 12
AYVAKIT 126, 127, 128
azathioprine oral tablet 50 mg 230
B
bac 77
BAFIERTAM..... 107, 108
BALVERSA..... 126, 127, 128
BENLYSTA SUBCUTANEOUS..... 14
BESREMI 15
BETASERON SUBCUTANEOUS KIT 107,
108
bexarotene 126, 127, 128, 195
bosentan 16
BOSULIF..... 126, 127, 128
BRAFTOVI ORAL CAPSULE 75 MG. 126,
127, 128
BRONCHITOL 102
BRUKINSA 126, 127, 128
budesonide er oral tablet extended release 24
hour 17
budesonide inhalation suspension 0.25
mg/2ml, 0.5 mg/2ml, 1 mg/2ml 230
butalbital-acetaminophen oral tablet 50-325
mg 77

Formulary ID 24425

Last Updated: 03/2024

| | |
|--|---------------|
| butalbital-apap-caff-cod oral capsule 50-325-40-30 mg..... | 77 |
| butalbital-apap-caffeine oral capsule 50-325-40 mg..... | 77 |
| butalbital-apap-caffeine oral tablet 50-325-40 mg..... | 77 |
| butalbital-asa-caff-codeine | 77 |
| butalbital-aspirin-caffeine oral capsule..... | 77 |
| C | |
| CABLIVI..... | 18 |
| CABOMETYX..... | 126, 127, 128 |
| CALQUENCE..... | 126, 127, 128 |
| CAMCEVI | 65 |
| CAMZYOS | 19, 20 |
| CAPLYTA | 129 |
| CAPRELSA..... | 126, 127, 128 |
| carglumic acid oral tablet soluble..... | 21 |
| carisoprodol oral | 78 |
| casprofungin acetate | 22 |
| CAYSTON | 13 |
| CERDELGA..... | 23 |
| chlorzoxazone oral tablet 500 mg | 78 |
| CHOLBAM..... | 26 |
| CIBINQO..... | 27 |
| CIMZIA STARTER KIT | |
| SUBCUTANEOUS PREFILLED | |
| SYRINGE KIT | 28, 29 |
| CIMZIA SUBCUTANEOUS KIT 2 X 200 | |
| MG | 28, 29 |
| CIMZIA SUBCUTANEOUS PREFILLED | |
| SYRINGE KIT | 28, 29 |
| CINRYZE..... | 70 |
| clemastine fumarate oral tablet 2.68 mg .. | 74, 75 |
| clinisol sf intravenous solution 15 % | 230 |
| clomipramine hcl oral..... | 76 |
| COMETRIQ (100 MG DAILY DOSE) | |
| ORAL KIT 80 & 20 MG | 126, 127, 128 |
| COMETRIQ (140 MG DAILY DOSE) | |
| ORAL KIT 3 X 20 MG & 80 MG..... | 126, 127, 128 |
| COMETRIQ (60 MG DAILY DOSE) .. | 126, 127, 128 |
| COPIKTRA..... | 126, 127, 128 |
| CORLANOR | 30 |

| | |
|---|---------------|
| CORTROPHIN | 31 |
| COSENTYX | 32 |
| COSENTYX (300 MG DOSE) | 32 |
| COSENTYX SENSOREADY (300 MG) | 32 |
| COSENTYX SENSOREADY PEN | 32 |
| COSENTYX UNOREADY | 32 |
| COTELLIC | 126, 127, 128 |
| cromolyn sodium inhalation nebulization | |
| solution 20 mg/2ml | 230 |
| CUVRIOR..... | 199 |
| cyclobenzaprine hcl oral tablet 10 mg, 5 mg | |
| | 78 |
| cyclophosphamide oral capsule 25 mg, 50 | |
| mg | 230 |
| cyclophosphamide oral tablet 25 mg, 50 mg | |
| | 230 |
| cyclosporine modified oral capsule 100 mg, | |
| 25 mg, 50 mg..... | 230 |
| cyclosporine modified oral solution 100 | |
| mg/ml..... | 230 |
| cyclosporine oral capsule 100 mg, 25 mg | 230 |
| cyproheptadine hcl oral | 74, 75 |
| CYSTAGON..... | 33 |
| CYSTARAN | 34 |
| D | |
| dalfampridine er | 35 |
| DAURISMO | 126, 127, 128 |
| deferasirox..... | 36 |
| deferasirox granules..... | 36 |
| deferiprone | 37 |
| DIACOMIT..... | 38 |
| dichlorphenamide | 39 |
| DIFICID..... | 40 |
| dimethyl fumarate oral..... | 107, 108 |
| dimethyl fumarate starter pack oral capsule | |
| delayed release therapy pack | 107, 108 |
| DIPHThERIA-TETANUS TOXOIDS DT | |
| INTRAMUSCULAR SUSPENSION 25- | |
| 5 LFU/0.5ML | 230 |
| dipyridamole oral..... | 74, 75 |
| disopyramide phosphate oral | 74, 75 |
| DOPTELET | 41 |
| doxepin hcl external..... | 42 |
| doxepin hcl oral capsule..... | 76 |
| doxepin hcl oral concentrate..... | 76 |

Formulary ID 24425

Last Updated: 03/2024

dronabinol oral capsule 10 mg, 2.5 mg, 5 mg
 230
 DUPIXENT 43, 44
E
 EGRIFTA SV 45
 ELIGARD 65
 EMEND ORAL SUSPENSION
 RECONSTITUTED 125 MG/5ML 230
 EMGALITY 24, 25
 EMGALITY (300 MG DOSE) 24, 25
 EMSAM 46
 ENBREL MINI 47
 ENBREL SUBCUTANEOUS SOLUTION
 25 MG/0.5ML 47
 ENBREL SUBCUTANEOUS SOLUTION
 PREFILLED SYRINGE 47
 ENBREL SUBCUTANEOUS SOLUTION
 RECONSTITUTED 47
 ENBREL SURECLICK SUBCUTANEOUS
 SOLUTION AUTO-INJECTOR 47
 ENDARI 48
 ENGERIX-B INJECTION SUSPENSION
 20 MCG/ML 230
 ENGERIX-B INJECTION SUSPENSION
 PREFILLED SYRINGE 10 MCG/0.5ML,
 20 MCG/ML 230
 ENTYVIO SUBCUTANEOUS 49
 ENVARUS XR ORAL TABLET
 EXTENDED RELEASE 24 HOUR 0.75
 MG, 1 MG, 4 MG 230
 EPIDIOLEX 50
 EPOGEN INJECTION SOLUTION 10000
 UNIT/ML, 2000 UNIT/ML, 20000
 UNIT/ML, 3000 UNIT/ML, 4000
 UNIT/ML 52
 EPRONTIA 51
 ERIVEDGE 126, 127, 128
 ERLEADA 126, 127, 128
 erlotinib hcl 126, 127, 128
 eszopiclone 79
 EUCRISA 53
 everolimus oral tablet 0.25 mg, 0.5 mg, 0.75
 mg, 1 mg 230
 everolimus oral tablet 10 mg, 2.5 mg, 5 mg,
 7.5 mg 126, 127, 128

everolimus oral tablet soluble .. 126, 127, 128
 EVRYSDI 54
 EXKIVITY 126, 127, 128
 EXTAVIA SUBCUTANEOUS KIT 107,
 108
F
 FABHALTA 55
 FANAPT 129
 FANAPT TITRATION PACK 129
 FASENRA 56
 FASENRA PEN 56
 fentanyl citrate buccal lozenge on a handle
 57
 fentanyl transdermal patch 72 hour 100
 mcg/hr 72, 73
 FILSPARI 58
 fingolimod hcl 107, 108
 FINTEPLA 59
 FIRDAPSE 60
 FIRMAGON (240 MG DOSE) 65
 FIRMAGON SUBCUTANEOUS
 SOLUTION RECONSTITUTED 80 MG
 65
 flucytosine oral 61
 fluorouracil external cream 0.5 % 62
 formoterol fumarate inhalation nebulization
 solution 20 mcg/2ml 230
 FOTIVDA 126, 127, 128
 FRUZAQLA 126, 127, 128
 FULPHILA 214
 FYLNETRA 214
G
 GALAFOLD 63
 GAMMAGARD INJECTION SOLUTION
 1 GM/10ML, 10 GM/100ML, 2.5
 GM/25ML, 20 GM/200ML, 30
 GM/300ML, 5 GM/50ML 230
 GAMMAGARD S/D LESS IGA
 INTRAVENOUS SOLUTION
 RECONSTITUTED 10 GM, 5 GM 230
 GAMMAKED INJECTION SOLUTION 1
 GM/10ML 230
 GAMMAPLEX INTRAVENOUS
 SOLUTION 10 GM/100ML, 10

Formulary ID 24425

GM/200ML, 20 GM/200ML, 5
 GM/50ML..... 230
 GAMUNEX-C INJECTION SOLUTION 1
 GM/10ML..... 230
 GATTEX..... 64
 GAVRETO..... 126, 127, 128
 gefitinib 126, 127, 128
 gengraf oral capsule 100 mg, 25 mg 230
 gengraf oral solution 100 mg/ml 230
 GENOTROPIN MINIQUICK
 SUBCUTANEOUS PREFILLED
 SYRINGE.....67, 68
 GENOTROPIN SUBCUTANEOUS
 CARTRIDGE67, 68
 GILOTRIF..... 126, 127, 128
 GLASSIA 7
 glatiramer acetate 107, 108
 glatopa..... 107, 108
 glyburide micronized oral tablet 1.5 mg, 3
 mg, 6 mg.....74, 75
 glyburide oral tablet 1.25 mg, 2.5 mg, 5 mg
74, 75
 glyburide-metformin oral tablet 1.25-250
 mg, 2.5-500 mg74, 75
 glyburide-metformin oral tablet 5-500 mg
74, 75
 GOCOVRI..... 66
 granisetron hcl oral tablet 1 mg..... 230
 guanfacine hcl er74, 75
 guanfacine hcl oral74, 75
H
 HADLIMA 69
 HADLIMA PUSH TOUCH 69
 HAEGARDA..... 70
 HEPLISAV-B INTRAMUSCULAR
 SOLUTION PREFILLED SYRINGE 20
 MCG/0.5ML 230
 HETLIOZ LQ..... 71
 HUMATROPE INJECTION CARTRIDGE
67, 68
 HUMIRA (2 PEN)80, 81
 HUMIRA (2 SYRINGE)
 SUBCUTANEOUS PREFILLED
 SYRINGE KIT 10 MG/0.1ML, 20

MG/0.2ML, 40 MG/0.4ML, 40
 MG/0.8ML 80, 81
 HUMIRA-CD/UC/HS STARTER
 SUBCUTANEOUS PEN-INJECTOR
 KIT 80 MG/0.8ML 80, 81
 HUMIRA-PED<40KG CROHNS
 STARTER..... 80, 81
 HUMIRA-PED>=40KG CROHNS START
 80, 81
 HUMIRA-PED>=40KG UC STARTER 80,
 81
 HUMIRA-PS/UV/ADOL HS STARTER 80,
 81
 HUMIRA-PSORIASIS/UVEIT STARTER
 80, 81
 hydroxyzine hcl oral syrup 74, 75
 hydroxyzine hcl oral tablet 25 mg, 50 mg 74,
 75
 hydroxyzine pamoate oral 74, 75
 HYFTOR82
I
 IBRANCE.....126, 127, 128
 icatibant acetate subcutaneous solution
 prefilled syringe83
 ICLUSIG..... 126, 127, 128
 icosapent ethyl.....84
 IDHIFA.....126, 127, 128
 ILARIS SUBCUTANEOUS SOLUTION 85
 ILUMYA86
 imatinib mesylate..... 126, 127, 128
 IMBRUVICA..... 87, 126, 127, 128
 imipramine hcl oral76
 imipramine pamoate76
 IMOVAX RABIES INTRAMUSCULAR
 SUSPENSION RECONSTITUTED 2.5
 UNIT/ML230
 INCRELEX.....88
 indomethacin er 74, 75
 indomethacin oral capsule 25 mg, 50 mg .74,
 75
 INGREZZA ORAL CAPSULE..... 210
 INGREZZA ORAL CAPSULE THERAPY
 PACK.....210
 INLYTA 126, 127, 128
 INQOVI.....126, 127, 128

Formulary ID 24425

Last Updated: 03/2024

| | |
|--|------------------|
| INREBIC..... | 126, 127, 128 |
| INTRALIPID INTRAVENOUS EMULSION 20 %, 30 % | 230 |
| INTRON A INJECTION SOLUTION RECONSTITUTED | 89 |
| INVEGA SUSTENNA INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 117 MG/0.75ML, 156 MG/ML, 234 MG/1.5ML, 39 MG/0.25ML, 78 MG/0.5ML..... | 139 |
| INVEGA TRINZA INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 273 MG/0.88ML, 410 MG/1.32ML, 546 MG/1.75ML, 819 MG/2.63ML..... | 139 |
| ipratropium bromide inhalation solution 0.02 % | 230 |
| ipratropium-albuterol inhalation solution 0.5-2.5 (3) mg/3ml | 231 |
| IWILFIN | 126, 127, 128 |
| J | |
| JAKAFI..... | 90 |
| JAYPIRCA..... | 126, 127, 128 |
| K | |
| KALYDECO | 91 |
| KERENDIA..... | 92 |
| KESIMPTA..... | 107, 108 |
| ketorolac tromethamine oral | 74, 75 |
| KEVZARA | 93 |
| KINERET SUBCUTANEOUS SOLUTION PREFILLED SYRINGE..... | 94 |
| KISQALI (200 MG DOSE).... | 126, 127, 128 |
| KISQALI (400 MG DOSE).... | 126, 127, 128 |
| KISQALI (600 MG DOSE).... | 126, 127, 128 |
| KISQALI FEMARA (200 MG DOSE) . | 126, 127, 128 |
| KISQALI FEMARA (400 MG DOSE) . | 126, 127, 128 |
| KISQALI FEMARA (600 MG DOSE) . | 126, 127, 128 |
| KORLYM..... | 95 |
| KOSELUGO..... | 126, 127, 128 |
| KRAZATI | 126, 127, 128 |
| L | |
| lapatinib ditosylate | 126, 127, 128 |
| lenalidomide..... | 126, 127, 128 |
| LENVIMA (10 MG DAILY DOSE) | 126, 127, 128 |
| LENVIMA (12 MG DAILY DOSE) | 126, 127, 128 |
| LENVIMA (14 MG DAILY DOSE) | 126, 127, 128 |
| LENVIMA (18 MG DAILY DOSE) | 126, 127, 128 |
| LENVIMA (20 MG DAILY DOSE) | 126, 127, 128 |
| LENVIMA (24 MG DAILY DOSE) | 126, 127, 128 |
| LENVIMA (4 MG DAILY DOSE) | 126, 127, 128 |
| LENVIMA (8 MG DAILY DOSE) | 126, 127, 128 |
| LEUKINE INJECTION SOLUTION RECONSTITUTED | 214 |
| leuprolide acetate (3 month)..... | 65 |
| levalbuterol hcl inhalation nebulization solution 0.31 mg/3ml, 0.63 mg/3ml, 1.25 mg/3ml | 231 |
| lidocaine external patch 5 %..... | 197 |
| LITFULO..... | 96 |
| LIVMARLI..... | 97 |
| LODOCO..... | 98 |
| LONSURF | 126, 127, 128 |
| LORBRENA | 126, 127, 128 |
| LUCEMYRA | 99 |
| LUMAKRAS | 126, 127, 128 |
| LUPKYNIS..... | 100 |
| LUPRON DEPOT (1-MONTH)..... | 65 |
| LUPRON DEPOT (3-MONTH)..... | 65 |
| LUPRON DEPOT (4-MONTH)..... | 65 |
| LUPRON DEPOT (6-MONTH)..... | 65 |
| LYBALVI..... | 101 |
| LYNPARZA ORAL TABLET | 126, 127, 128 |
| LYTGOBI (12 MG DAILY DOSE) | 126, 127, 128 |
| LYTGOBI (16 MG DAILY DOSE) | 126, 127, 128 |
| LYTGOBI (20 MG DAILY DOSE) | 126, 127, 128 |

Formulary ID 24425

M

MAVENCLAD (10 TABS)..... 107, 108
MAVENCLAD (4 TABS)..... 107, 108
MAVENCLAD (5 TABS)..... 107, 108
MAVENCLAD (6 TABS)..... 107, 108
MAVENCLAD (7 TABS)..... 107, 108
MAVENCLAD (8 TABS)..... 107, 108
MAVENCLAD (9 TABS)..... 107, 108
MAVYRET 103
MAYZENT 107, 108
MAYZENT STARTER PACK..... 107, 108
megestrol acetate oral suspension 74, 75
megestrol acetate oral tablet 76
MEKINIST..... 126, 127, 128
MEKTOVI 126, 127, 128
MENEST..... 76
metaxalone oral tablet 800 mg 78
methadone hcl oral tablet 10 mg 72, 73
methocarbamol oral tablet 500 mg, 750 mg
..... 78
methyltestosterone oral..... 104
metyrosine 105
mifepristone oral tablet 300 mg 95
miglustat..... 106
modafinil oral 117
morphine sulfate er oral tablet extended
release 100 mg, 200 mg 72, 73
mycophenolate mofetil oral capsule 250 mg
..... 231
mycophenolate mofetil oral suspension
reconstituted 200 mg/ml 231
mycophenolate mofetil oral tablet 500 mg
..... 231
mycophenolate sodium oral tablet delayed
release 180 mg, 360 mg 231
mycophenolic acid oral tablet delayed
release 180 mg, 360 mg 231
MYFEMBREE 109
N
NATPARA 111
NAYZILAM..... 110
NERLYNX..... 126, 127, 128
NEULASTA ONPRO 214
NEULASTA SUBCUTANEOUS
SOLUTION PREFILLED SYRINGE 214

NEXLETOL..... 112, 113
NEXLIZET 114, 115
NGENLA 67, 68
nifedipine oral 74, 75
nilutamide 126, 127, 128
NINLARO..... 126, 127, 128
nitisinone..... 116
NORDITROPIN FLEXPRO
SUBCUTANEOUS SOLUTION PEN-
INJECTOR..... 67, 68
NORPACE CR..... 74, 75
NUBEQA..... 126, 127, 128
NUCALA..... 118, 119
NUEDEXTA..... 120
NULOJIX INTRAVENOUS SOLUTION
RECONSTITUTED 250 MG 231
NUPLAZID ORAL CAPSULE..... 121
NUPLAZID ORAL TABLET 10 MG ... 121
NURTEC 24, 25
NUTRILIPID INTRAVENOUS
EMULSION 20 % 231
NUTROPIN AQ NUSPIN 10
SUBCUTANEOUS SOLUTION PEN-
INJECTOR..... 67, 68
NUTROPIN AQ NUSPIN 20
SUBCUTANEOUS SOLUTION PEN-
INJECTOR..... 67, 68
NUTROPIN AQ NUSPIN 5
SUBCUTANEOUS SOLUTION PEN-
INJECTOR..... 67, 68
NYVEPRIA 214
O
OCALIVA..... 122
octreotide acetate injection solution 100
mcg/ml, 1000 mcg/ml, 200 mcg/ml, 50
mcg/ml, 500 mcg/ml 123
ODOMZO 126, 127, 128
OFEV 124
OGSIVEO..... 126, 127, 128
OJJAARA 126, 127, 128
OLUMIANT 125
OMNITROPE SUBCUTANEOUS
SOLUTION CARTRIDGE 67, 68
OMNITROPE SUBCUTANEOUS
SOLUTION RECONSTITUTED ... 67, 68

Formulary ID 24425

Last Updated: 03/2024

ondansetron hcl oral solution 4 mg/5ml . 231
ondansetron hcl oral tablet 24 mg, 4 mg, 8
mg 231
ondansetron oral tablet dispersible 4 mg, 8
mg 231
ONUREG 126, 127, 128
ORENCIA CLICKJECT 130
ORENCIA INTRAVENOUS 130
ORENCIA SUBCUTANEOUS SOLUTION
PREFILLED SYRINGE 130
ORFADIN ORAL SUSPENSION 116
ORGOVYX 126, 127, 128
ORIAHNN 131
ORILISSA 132
ORKAMBI 133
ORLADEYO 70
orphenadrine citrate er 78
ORSERDU 126, 127, 128
OTEZLA 134
OXBRYTA 135
OXERVATE 136
oxycodone hcl er oral tablet er 12 hour
abuse-deterrent 10 mg, 20 mg, 40 mg 137,
138
oxycodone hcl er oral tablet er 12 hour
abuse-deterrent 80 mg 72, 73

P

paliperidone er oral tablet extended release
24 hour 1.5 mg, 3 mg, 6 mg, 9 mg 140
PANRETIN 195
pazopanib hcl 126, 127, 128
PEGASYS SUBCUTANEOUS SOLUTION
180 MCG/ML 143
PEGASYS SUBCUTANEOUS SOLUTION
PREFILLED SYRINGE 143
PEMAZYRE 127, 128
penicillamine oral tablet 144
pentamidine isethionate inhalation solution
reconstituted 300 mg 231
pentamidine isethionate injection 145
pentazocine-naloxone hcl 74, 75
perphenazine-amitriptyline 76
PERSERIS 146
phenobarbital oral elixir 76
phenobarbital oral tablet 76

phenoxybenzamine hcl oral 147
PIQRAY (200 MG DAILY DOSE) 127, 128
PIQRAY (250 MG DAILY DOSE) 127, 128
PIQRAY (300 MG DAILY DOSE) 127, 128
pirfenidone 148
plenamine intravenous solution 15 % 231
POMALYST 127, 128
PONVORY 107, 108
PONVORY STARTER PACK 107, 108
posaconazole oral 149
PRALUENT SUBCUTANEOUS
SOLUTION AUTO-INJECTOR 141, 142
PREHEVBRIO INTRAMUSCULAR
SUSPENSION 10 MCG/ML 231
PRETOMANID 150
PREVYMIS ORAL 151
PRIVIGEN INTRAVENOUS SOLUTION
10 GM/100ML, 20 GM/200ML, 40
GM/400ML, 5 GM/50ML 231
PROCRIT 52
PROGRAF INTRAVENOUS SOLUTION 5
MG/ML 231
PROGRAF ORAL PACKET 0.2 MG, 1 MG
..... 231
PROLASTIN-C 7
PROLIA SUBCUTANEOUS SOLUTION
PREFILLED SYRINGE 152
PROMACTA ORAL PACKET 12.5 MG,
25 MG 153
PROMACTA ORAL TABLET 12.5 MG, 25
MG, 50 MG, 75 MG 153
promethazine hcl oral 74, 75
promethazine hcl rectal suppository 12.5
mg, 25 mg 74, 75
promethazine vc 74, 75
promethazine-phenylephrine 74, 75
promethegan rectal suppository 50 mg 74, 75
protriptyline hcl 76
PULMOZYME INHALATION
SOLUTION 2.5 MG/2.5ML 231
PURIXAN 127, 128
PYRUKYND 154
PYRUKYND TAPER PACK 154

Q

QINLOCK 127, 128

Formulary ID 24425

R
RABA VERT INTRAMUSCULAR
SUSPENSION RECONSTITUTED .. 231
RADICAVA ORS..... 155
RADICAVA ORS STARTER KIT..... 155
RAVICTL..... 156
REBIF REBIDOSE SUBCUTANEOUS
SOLUTION AUTO-INJECTOR. 107, 108
REBIF REBIDOSE TITRATION PACK
SUBCUTANEOUS SOLUTION AUTO-
INJECTOR 107, 108
REBIF SUBCUTANEOUS SOLUTION
PREFILLED SYRINGE..... 107, 108
REBIF TITRATION PACK
SUBCUTANEOUS SOLUTION
PREFILLED SYRINGE..... 107, 108
RECOMBIVAX HB INJECTION
SUSPENSION 10 MCG/ML, 40
MCG/ML, 5 MCG/0.5ML 231
RECOMBIVAX HB INJECTION
SUSPENSION PREFILLED SYRINGE
10 MCG/ML, 5 MCG/0.5ML 231
RECORLEV 157
REGRANEX 158
RELISTOR ORAL..... 159
RELISTOR SUBCUTANEOUS
SOLUTION 159
RELYVRIO..... 160
REPATHA 141, 142
REPATHA PUSHTRONEX SYSTEM. 141,
142
REPATHA SURECLICK..... 141, 142
RETACRIT INJECTION SOLUTION
10000 UNIT/ML, 10000
UNIT/ML(1ML), 2000 UNIT/ML, 20000
UNIT/ML, 3000 UNIT/ML, 4000
UNIT/ML, 40000 UNIT/ML 52
RETEVMO..... 127, 128
REVLIMID 127, 128
REXULTI..... 161
REZLIDHIA..... 127, 128
REZUROCK..... 162
RINVOQ 163, 164
risperidone microspheres er 165
ROZLYTREK 127, 128

RUBRACA 127, 128
rufinamide oral suspension..... 166
rufinamide oral tablet..... 166
RYDAPT 127, 128
RYKINDO 167
RYLAZE..... 168
S
SANDIMMUNE ORAL SOLUTION 100
MG/ML231
sapropterin dihydrochloride oral packet.. 169
sapropterin dihydrochloride oral tablet ... 169
SCEMBLIX 127, 128
SECUADO..... 170
SEROSTIM SUBCUTANEOUS
SOLUTION RECONSTITUTED 4 MG,
5 MG, 6 MG 171
SIGNIFOR 172
sildenafil citrate oral suspension
reconstituted 173
sildenafil citrate oral tablet 20 mg 173
SILIQ 174
SIMPONI SUBCUTANEOUS SOLUTION
AUTO-INJECTOR 175
SIMPONI SUBCUTANEOUS SOLUTION
PREFILLED SYRINGE..... 175
sirolimus oral solution 1 mg/ml231
sirolimus oral tablet 0.5 mg, 1 mg, 2 mg.231
SIRTURO 176
SKYRIZI..... 177
SKYRIZI PEN..... 177
SKYTROFA..... 67, 68
sodium oxybate.....223
sodium phenylbutyrate oral powder 3 gm/tsp
..... 178
sodium phenylbutyrate oral tablet..... 178
SOFOSBUVIR-VELPATASVIR..... 179
SOLTAMOX..... 127, 128
SOMAVERT..... 180
sorafenib tosylate 127, 128
SOTYKTU 181
SPRYCEL..... 127, 128
STELARA INTRAVENOUS..... 182
STELARA SUBCUTANEOUS
SOLUTION 45 MG/0.5ML..... 182

Formulary ID 24425

Last Updated: 03/2024

| | |
|---|----------|
| STELARA SUBCUTANEOUS | |
| SOLUTION PREFILLED SYRINGE | 182 |
| STIVARGA..... | 127, 128 |
| SUCRAID | 183 |
| sunitinib malate..... | 127, 128 |
| SYMDEKO | 184 |
| SYMLINPEN 120 SUBCUTANEOUS | |
| SOLUTION PEN-INJECTOR..... | 185 |
| SYMLINPEN 60 SUBCUTANEOUS | |
| SOLUTION PEN-INJECTOR..... | 185 |
| SYNAREL | 186 |
| T | |
| TABLOID | 127, 128 |
| TABRECTA..... | 127, 128 |
| tacrolimus oral capsule 0.5 mg, 1 mg, 5 mg | |
| | 231 |
| tadalafil (pah)..... | 187 |
| TADLIQ..... | 187 |
| TAFINLAR | 127, 128 |
| TAGRISSO | 127, 128 |
| TALTZ..... | 188 |
| TALZENNA..... | 127, 128 |
| TARPEYO | 189 |
| TASCENSO ODT..... | 107, 108 |
| TASIGNA | 127, 128 |
| tasimelteon | 71 |
| TAVNEOS | 190 |
| TAZVERIK..... | 127, 128 |
| TDVAX INTRAMUSCULAR | |
| SUSPENSION 2-2 LF/0.5ML | 231 |
| TEFLARO..... | 191 |
| temazepam..... | 79 |
| TENIVAC INTRAMUSCULAR | |
| INJECTABLE 5-2 LFU, 5-2 LFU | |
| (INJECTION) | 231 |
| TEPMETKO..... | 127, 128 |
| teriflunomide | 107, 108 |
| teriparatide..... | 192 |
| teriparatide (recombinant) subcutaneous | |
| solution pen-injector 600 mcg/2.4ml.. | 192 |
| TERIPARATIDE (RECOMBINANT) | |
| SUBCUTANEOUS SOLUTION PEN- | |
| INJECTOR 620 MCG/2.48ML..... | 192 |
| testosterone transdermal gel 1.62 %, 12.5 | |
| mg/act (1%), 20.25 mg/1.25gm (1.62%), | |
| 20.25 mg/act (1.62%), 25 mg/2.5gm | |
| (1%), 40.5 mg/2.5gm (1.62%), 50 | |
| mg/5gm (1%)..... | 196 |
| testosterone transdermal solution..... | 196 |
| TETANUS-DIPHThERIA TOXOIDS TD | |
| INTRAMUSCULAR SUSPENSION 2-2 | |
| LF/0.5ML..... | 231 |
| tetrabenazine | 210 |
| THALOMID | 127, 128 |
| THIOLA EC..... | 193 |
| TIBSOVO | 127, 128 |
| tiopronin oral | 193 |
| tobramycin inhalation nebulization solution | |
| 300 mg/5ml | 231 |
| tolvaptan | 194 |
| toremifene citrate..... | 127, 128 |
| TRELSTAR MIXJECT..... | 65 |
| TREMFYA | 198 |
| tretinoin oral..... | 127, 128 |
| trientine hcl oral capsule 250 mg..... | 199 |
| trihexyphenidyl hcl | 74, 75 |
| TRIKAFTA..... | 200 |
| trimipramine maleate oral | 76 |
| TRUQAP | 127, 128 |
| TRUSELTIQ (100MG DAILY DOSE) . | 127, |
| 128 | |
| TRUSELTIQ (125MG DAILY DOSE) . | 127, |
| 128 | |
| TRUSELTIQ (50MG DAILY DOSE) ... | 127, |
| 128 | |
| TRUSELTIQ (75MG DAILY DOSE) ... | 127, |
| 128 | |
| TUKYSA | 127, 128 |
| TURALIO..... | 127, 128 |
| TYMLOS..... | 201 |
| TYVASO DPI MAINTENANCE KIT ... | 202 |
| TYVASO DPI TITRATION KIT | |
| INHALATION POWDER 16 & 32 & 48 | |
| MCG | 202 |
| U | |
| UBRELVY..... | 24, 25 |
| UDENYCA..... | 214 |
| UDENYCA ONBODY | 214 |
| UPTRAVI ORAL..... | 203 |
| UPTRAVI TITRATION | 203 |

Formulary ID 24425

Last Updated: 03/2024

| | | | |
|--|-------------|--|-------------|
| UZEDY | 204 | XPOVIO (60 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 60 MG . | 127, 128 |
| V | | XPOVIO (60 MG TWICE WEEKLY) .. | 127, 128 |
| VALCHLOR | 205 | XPOVIO (80 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 40 MG . | 127, 128 |
| VALTOCO 10 MG DOSE | 110 | XPOVIO (80 MG TWICE WEEKLY) .. | 127, 128 |
| VALTOCO 15 MG DOSE | 110 | XTANDI..... | 127, 128 |
| VALTOCO 20 MG DOSE | 110 | XURIDEN..... | 222 |
| VALTOCO 5 MG DOSE | 110 | XYREM..... | 223 |
| VANFLYTA..... | 127, 128 | XYWAV | 224 |
| VEMLIDY | 206 | Y | |
| VENCLEXTA | 127, 128 | YONSA..... | 127, 128 |
| VENCLEXTA STARTING PACK. | 127, 128 | Z | |
| VENTAVIS | 207 | zaleplon..... | 79 |
| VERZENIO..... | 127, 128 | ZARXIO | 214 |
| vigabatrin..... | 208 | ZAVZPRET | 24, 25 |
| VIJOICE..... | 209 | ZEJULA..... | 127, 128 |
| VITRAKVI..... | 127, 128 | ZELBORAF..... | 127, 128 |
| VIZIMPRO..... | 127, 128 | ZEMAIRA | 7 |
| VONJO..... | 127, 128 | ZEPOSIA | 225 |
| voriconazole intravenous..... | 211 | ZEPOSIA 7-DAY STARTER PACK..... | 225 |
| VOSEVI..... | 212 | ZEPOSIA STARTER KIT ORAL CAPSULE THERAPY PACK 0.23MG &0.46MG 0.92MG(21) | 225 |
| VOWST | 213 | ZIEXTENZO..... | 214 |
| VRAYLAR ORAL CAPSULE..... | 129 | ZILBRYSQ..... | 226 |
| VRAYLAR ORAL CAPSULE THERAPY PACK..... | 129 | ZOLINZA | 127, 128 |
| W | | zolpidem tartrate er | 79 |
| WELIREG..... | 127, 128 | zolpidem tartrate oral tablet 10 mg | 79 |
| X | | ZTALMY | 227 |
| XALKORI..... | 127, 128 | ZTLIDO..... | 197 |
| XATMEP | 215 | ZURZUVAE | 228 |
| XELJANZ | 216 | ZYDELIG | 127, 128 |
| XELJANZ XR..... | 216 | ZYKADIA ORAL TABLET..... | 127, 128 |
| XERMELO..... | 217 | ZYPREXA RELPREVV INTRAMUSCULAR SUSPENSION RECONSTITUTED 210 MG, 300 MG, 405 MG..... | 229 |
| XGEVA..... | 218 | | |
| XIFAXAN..... | 219 | | |
| XOLAIR..... | 220, 221 | | |
| XOSPATA | 127, 128 | | |
| XPOVIO (100 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 50 MG | 127, 128 | | |
| XPOVIO (40 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 40 MG | 127, 128 | | |
| XPOVIO (40 MG TWICE WEEKLY) ORAL TABLET THERAPY PACK 40 MG..... | 127, 128 | | |

Formulary ID 24425

Last Updated: 03/2024

Formulary ID 24425

Last Updated: 03/2024
242